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ABSTRACT 
Adherence to psychotropic medication is a critical aspect of treatment for the management of 
psychotic disorders. While the literature on the need for medication adherence is extensive, little 
research has explored the relationship between the negative symptoms of psychosis and 
medication adherence. Since negative symptoms are enduring, stable, and strongly correlated 
with poor outcome, it is vitally important for research to explore the role of negative symptoms 
in regards to adherence to psychotropic medication. Given its potentially significant 
consequences for treatment interventions, the purpose of this study was to contribute to the 
exceedingly limited body of research exploring the relationship between the negative symptoms 
seen in psychosis and medication adherence. This study examined if there is a relationship 
between the two and whether causality could be determined should a significant relationship 
exist between medication adherence and negative symptoms. This study utilized data previously 
collected at the UCLA Aftercare Research Program for studies examining aspects of outpatient 
psychiatric treatment. The 148 participants had a mean age of 22.5 years and were in the midst of 
their first psychotic episode upon study entry. Data from the Brief Psychiatric Rating Scale, 
Scale for the Assessment of Negative Symptoms, and medication adherence ratings were 
collected over the course of 12 months. Analyses revealed a significant relationship between the 
presence of negative symptoms and medication nonadherence. Analyses examining the temporal 
relationship between the two variables revealed that initial medication nonadherence was 
significantly associated with subsequent negative symptoms. However, once the impact of 
positive symptoms was controlled for as a potential mediating variable, the strength of the 
relationship between medication adherence and negative symptoms dissipated. After controlling 
for the role of reality distortion, the only negative symptoms significantly associated with 
	  xxv 
medication nonadherence were the BPRS Negative Symptom Factor, BPRS Emotional 
Withdrawal, and BPRS Self-Neglect. Consequently, it appears that negative symptoms are more 
strongly associated with positive symptoms than with medication adherence. Replication of these 
findings and further research exploring the relationship between positive and negative symptoms 
as they relate to medication adherence is needed in order to improve treatment interventions 
focused on medication adherence.  
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Chapter 1: Review of the Literature 
Introduction 
Schizophrenia is a life-long and often debilitating illness, impacting all aspects of one’s 
life. Adding to the difficulty and complexity of treating the disorder is the reality that the 
presentation of the illness can be highly varied in terms of the specific constellation of symptoms 
displayed and their severity. As a result, understanding the relationship between aspects of the 
illness and treatment effectiveness can be challenging.  Although the terminology of positive vs. 
negative symptoms originated with the neurologist Hughlings Jackson in the 1930s, the 
observation that schizophrenia symptoms can be conceptualized into two general clusters has 
been made for over 150 years (Berrios, 1985; Crow, 1985; Hughlings-Jackson, 1931; Tandon et 
al., 2013). Positive symptoms are exaggerations and distortions of normal perception and 
thinking, such as paranoia, delusions, and hallucinations (Fernandez, Gomez, Homero, & Lopez-
Ibor, 2013; Rollins, Bond, Lysaker, McGrew, & Salyers, 2010). Positive symptoms are among 
the features of schizophrenia that the public most often associates with psychosis and may be 
more intrusive than negative symptoms; however, negative symptoms are more highly correlated 
with poor outcome and long-term impairment in functioning (Hanson, Healey, Wolf, & Kohler, 
2010). Although positive symptoms are a core feature of schizophrenia, for the purposes of this 
dissertation, emphasis will be placed on negative symptoms, with little further reference to 
positive symptoms.  
Negative symptoms reflect the absence or reduction of certain social abilities and 
emotions that are normally present (Hanson et al., 2010; Moller, 2007). Although the inclusion 
of negative symptoms as an example of active phase symptoms of schizophrenia in the DSM 
system is of relatively recent origin (American Psychological Association [APA], 2000), 
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historically there has been an understanding of the importance of negative symptoms in the 
disease process of schizophrenia.  For example, Bleuler prioritized negative symptoms over 
positive symptoms as primary aspects of schizophrenia (Hanson et al., 2010). A challenge in 
identifying negative symptoms is determining whether they are primary features of the illness or 
secondary to factors such as hospitalization, depression, environmental understimulation, and 
medication side effects (Chang et al., 2011; Flaum & Andreasen, 1995). If it is determined that 
the presence of negative symptoms is due to any other factor, then the negative symptoms should 
not be considered a factor for the diagnosis of schizophrenia (APA, 2013).  Since secondary 
symptoms can be due to several factors, they often fluctuate based on the changes of the 
influencing factors (Hanson et al., 2010).  
This dissertation will explore the relationship between negative symptoms of first episode 
schizophrenia and medication nonadherence. As such, the following includes a review of various 
aspects of negative symptoms, including types and examples of negative symptoms, clinical 
significance and prognosis, and the relationship between negative symptoms and medication 
adherence. 
Negative Symptoms  
Negative symptoms are important in understanding and treating schizophrenia because 
there is robust evidence that outcome is predicted by severity of negative symptoms and 
cognitive impairment (Brier & Berg, 1999; Ventura, Hellemann, Thames, Koellner, & 
Nuechterlein, 2009). Although research has established the effectiveness of antipsychotic 
medications on treating positive symptoms (Kozuki & Schepp, 2005; Leucht et al., 2003; Salimi, 
Jarskog, & Lieberman, 2009), these agents are not as effective in treating negative symptoms or 
cognitive deficits (Breier & Berg, 1999; Erhart, Marder, & Carpenter, 2006; Salimi et al., 2009). 
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Despite negative symptoms being less responsive to treatment, persistent, and worsening over 
time, they are typically viewed as less disruptive and distressing than positive symptoms because 
they do not usually lead to hospitalization (Hanson et al., 2010). Negative symptoms associated 
with schizophrenia tend to be fairly stable throughout the course of the illness and are less likely 
to characterize cases with later illness onset (Woo & Keatinge, 2008). Additionally, negative 
symptoms manifest in many ways, which adds to the complexity of the clinical presentation of 
schizophrenia and its treatment (Moller, 2007). It can be particularly difficult for the individual 
with schizophrenia and their loved ones because oftentimes negative symptoms can seem very 
similar to clinical depression since both share a lack of motivation, decreased interests, or just an 
inability to be interested in anything; these similarities can make it challenging for clinicians to 
properly distinguish between schizophrenia and a mood disorder (Green, 2001). Additionally, 
negative symptoms may be particularly difficult for loved ones because individuals with mostly 
negative symptoms of schizophrenia often appear interpersonally disconnected, bland, or 
“zombie-like” (Woo & Keatinge, 2008, p. 477). One psychologist, John Briere, has even likened 
it to talking to someone with “a sheet of plastic” (personal communication, December 17, 2012) 
between oneself and an individual with schizophrenia.  
Types of negative symptoms. There are many types of negative symptoms that can be a 
part of schizophrenia. To better understand the breadth negative symptoms have in an 
individual’s overall functioning, the most common ones will be identified and described: 
Affective flattening, alogia, apathy, anergia, avolition, anhedonia, and asociality. 
Affective flattening, also called blunted affect, involves restrictions in the range and 
intensity of one’s emotional expression and is characterized by poor eye contact, immobility in 
the face, and reduced body language (APA, 2000; Green, 2001). The individual may smile or 
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warm up to someone occasionally, but mostly there is a restricted and diminished range of 
emotional expressiveness that is present most of the time (Tattan & Creed, 2001). Reduction of 
spontaneous movements and lack of voice modulation may also be present with affective 
flattening (Makinen, Miettunen, Isohanni, & Koponen, 2008). 
Alogia, also known as poverty of speech, consists of restrictions or a decrease in the 
fluency and productivity of thought or speech and may be manifest by brief, concise, empty 
replies that are not attributable to factors such as an unwillingness to speak (APA, 2000; Green, 
2001; Rollins et al., 2010; Tattan & Creed, 2001). Individuals with alogia tend to talk little and 
say few words (Makinen et al., 2008). 
Apathy refers to the absence, suppression, or withdrawal of emotions or feelings (Rollins 
et al., 2010; Tattan & Creed, 2001). Apathy reflects a lack of motivation and a decrease in goal-
directed behavior not attributable to cognitive impairment, emotional distress, or decreased 
consciousness (Kiang, Christensen, Remington, & Kapur, 2003). When an individual 
demonstrates apathy, it may look like she or he has an indifference to everything – relationships, 
long-term goals, or the future in general. Those with schizophrenia may also be unable to 
articulate or only poorly describe their feelings (Woo & Keatinge, 2008). 
Anergia is a physical symptom that consists of a reduction in movement or a lack of 
energy (Green, 2001; Woo & Keatinge, 2008). Anergia may look like motor retardation and 
disorientation (Laroi et al., 2000). It consists of slow or restricted physical movement, and may 
also relate to poor mental focus (Moller, 2007). 
Avolition, also known as amotivation, refers to a restriction in the initiation or persistence 
of goal-directed behavior or activities (APA, 2000; Foussias & Remington, 2010). Avolition also 
includes reduced motivation, which may be evidenced by behaviors such as poor hygiene 
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(Makinen et al., 2008). Individuals with this symptom may display a decreased willingness to or 
interest in work, school, social, treatment, or recreational activities and may instead sit for long 
periods of time (APA, 2000; Baier et al., 2000; Leo, Jassal, & Bakhai, 2005). Since avolition 
may include spending days sitting and watching television, having no interest in helping with 
basic household chores, or seeming unwilling to return to school or obtain a job, it can 
sometimes be viewed as a personality flaw instead of a symptom of schizophrenia (Green, 2001).  
Anhedonia represents a loss of interest or pleasure in activities (APA, 2000; Baier et al., 
2000; Foussias & Remington, 2010; Loas, Noisette, Legrand, & Boyer, 2000). It is also thought 
of as a diminished capacity for experiencing pleasure, and can manifest not just as loss of interest 
but also less engagement in social or pleasurable activities (Buck & Lysaker, 2013; Makinen et 
al., 2008). The inability to experience closeness with others is also associated with anhedonia 
(Makinen et al., 2008). 
Asociality is social withdrawal due to a lack of motivation to engage in social 
interactions, and a preference for solitary activities (Tattan & Creed, 2001; Woo & Keatinge, 
2008). Individuals experiencing asociality may have few friends, poor relations with friends, and 
reduced social interactions with others (Makinen et al., 2008). 
Deficit syndrome. Deficit syndrome is a term coined by Carpenter and his colleagues in 
1988 that is intended to reflect primary negative symptoms that are characterized by an enduring 
stability and persistence over time that are not attributable to secondary symptoms (APA, 2000; 
Carpenter, Heinrichs, & Wagman, 1988; Chang et al., 2011). The deficit syndrome is associated 
with anticipatory anhedonia (i.e., lack of motivated behavior and a desire for something in the 
future; Buck & Lysaker, 2013) and cognitive dysfunction, and those with the deficit syndrome 
tend to have more neurocognitive deficits than individuals with schizophrenia who do not have 
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the deficit syndrome (Beck et al., 2011; Green, 2001; Hanson et al., 2010). Additionally, the 
deficit syndrome has been associated with lower socio-economic status, irrespective of ethnicity 
(Hanson Healey, Wolf, & Kohler, 2010).  The deficit syndrome has been found to be directly 
related to functional outcomes including decreased employment and social functioning, lower 
socio-economic status, and overall worse prognosis (Green, 2001; Hanson et al., 2010). Notably, 
one study showed that when receiving social skills training, individuals with the deficit 
syndrome benefited less than individuals without deficit syndrome (Erhart et al., 2006). Overall, 
the estimated prevalence of the deficit syndrome is 15% for first episode schizophrenia, and 25-
30% in chronic schizophrenia (Hanson et al., 2010; Kirkpatrick, Buchanan, Ross, & Carpenter, 
2001).   
Clinical Significance of Negative Symptoms 
Negative symptoms are typically stable and enduring features of schizophrenia, lasting 
throughout the course of the illness (Hanson et al., 2010; Rollins et al., 2010). Approximately 50-
90% of individuals with schizophrenia experience negative symptoms during their first episode 
of psychosis, and 20-40% of individuals with schizophrenia have persistent negative symptoms 
(Makinen et al., 2008). Further, overall functioning, quality of life, and aspects of everyday life 
are profoundly affected by negative symptoms (Makinen et al., 2008; Rollins et al., 2010). 
Negative symptoms tend to go unnoticed by the patient, but as previously noted are very 
noticeable to the individuals around the patient, and may worsen over time (Hanson et al., 2010; 
Rollins et al., 2010).  
Association Between Negative Symptoms and Outcome  
Although the presence of negative symptoms is generally agreed upon to indicate poor 
prognosis, evidence for the responsiveness of negative symptoms to medication is mixed (Erhart, 
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Marder, & Carpenter, 2006). First generation antipsychotic medications were first developed in 
the 1940s, and consisted of chlorpromazine, haloperidol, thioridazine, and fluphenazine (Green, 
2001). Although these medications revolutionized the treatment and prognosis for schizophrenia, 
they mostly treated positive symptoms and were not very effective at reducing negative 
symptoms (Carpenter & Davis, 2012). In the 1990s a new generation of antipsychotic 
medications, referred to as atypical antipsychotics, were introduced to the market and found to be 
more effective than previous agents in treating negative symptoms as well as the anxiety and 
depression that often accompany schizophrenia; however, such medication did not effectively 
treat negative symptoms (Green, 2001; Hanson et al., 2010). To clarify, it appears that atypical 
antipsychotics minimize secondary negative symptoms; however, they have no significant 
impact on primary negative symptoms (Hanson et al., 2010). Even up to recently, available 
pharmacological treatments have had limited benefits in reducing the burden of negative 
symptoms (Erhart, Marder, & Carpenter, 2006; Makinen, Miettunen, Isohanni, & Koponen, 
2008). However clozapine appears to be the most effective atypical antipsychotic medication for 
treatment of negative symptoms, but comes with a serious risk of agranulocytosis (Makinen et 
al., 2008). The second-generation antipsychotic iloperidone, appears to be superior to haloperidol 
or risperidone in improving negative symptoms, but appears to have a greater effect on 
secondary and not primary negative symptoms (Hanson et al., 2010). Asenapine has 
demonstrated some efficacy for persistent negative symptoms when compared to olanzapine, 
though superiority has not been demonstrated (Hanson et al., 2010). When compared to 
haloperidol, both olanzapine and risperidone demonstrate clinically significant improvement for 
the extent of negative symptoms (Hartling et al., 2012; Salimi, Jarskog, & Lieberman, 2009). 
Overall, research seems to indicate that clozapine, olanzapine, and risperidone are more effective 
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in treating negative symptoms than typical antipsychotics (Makinen et al., 2008). In one study, 
olanzapine and risperidone were each associated with moderate improvements in avolition and 
apathy, with a mild, but non-significant effect for asociality and anhedonia (Salimi, Jarskog, & 
Lieberman, 2009). Affective flattening and poverty of speech appear to be more stable and less 
responsive to pharmacologic treatment (Kelley, van Kammen, & Allen, 1999). Although second-
generation antipsychotics generally have fewer side-effects than first-generation antipsychotics, 
it must be acknowledged that clozapine and olanzapine can cause serious side effects such as 
diabetes and weight gain (Thomas, Nandhra, & Singh, 2012). Limited positive findings have 
been associated with N-methyl-D-aspartate agonists, and cognitive enhancers have had mixed 
results for reducing negative symptoms (Hanson et al., 2010). Promising preliminary results for 
treating negative symptoms have been found with minocycline and omega fatty acids (Hanson et 
al., 2010).  
As previously mentioned, it is generally agreed upon that the presence of negative 
symptoms in schizophrenia, particularly in the earlier stages of the illness, is associated with 
poor prognosis and functional outcome, and limited response to medication (Makinen et al., 
2008; Ventura et al., 2009). In fact, individuals with persistent negative symptoms are 
significantly more likely to be male, have more prominent symptoms, less insight, worse 
vocational outcome, and spend less time in full-time employment (Chang et al., 2011). 
Individuals with persistent negative symptoms have also been found to have longer duration of 
untreated psychosis and poorer premorbid functioning in academic and occupational function 
than individuals without primary negative symptoms (Chang et al., 2011). Thus negative 
symptoms can be extremely detrimental to an individual’s future and can impair the overall level 
of functioning. Even after a psychotic episode has resolved, negative symptoms often remain, 
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making it hard for individuals to reestablish a sense of interpersonal connectedness with others 
(Green, 2001). So far, no treatment appears to significantly treat and improve the negative 
symptoms of schizophrenia (Carpenter & Davis, 2012; Moller, 2007). 
Medication Adherence 
It is important to discuss the role of medication adherence in the treatment of 
schizophrenia. Steger, Cassidy, Rabinovitch, Joober, & Malla (2012) found that within first 
episode psychosis, medication adherence has been associated with faster remission of positive 
symptoms, better social and occupational functioning, and fewer relapses (Coldham, Addington, 
& Addington, 2002). In general, strong medication adherence has been shown to improve overall 
outcomes in psychosis by reducing the risk of relapse and rehospitalization (Steger et al., 2012). 
Additionally, individuals who have a history of nonadherence or who are initially nonadherent to 
medication are much more likely to be inadequately adherent throughout the course of the 
illness, as past nonadherence is predictive of future nonadherence (Leo et al., 2005; Steger et al., 
2012). 
There are a range of definitions of medication adherence and measures used to assess this 
construct, which can make comparison of findings difficult (Novak-Grubic & Tavcar, 2002). 
Some of the many measures of medication adherence are electronic compliance monitors, pill 
counts, direct observation, prescription renewals, patient or relative report, and biological 
measurements such as blood assays (Coldham et al., 2002). For the purpose of this paper, the 
definition of medication adherence will be, “the extent to which a person’s behavior cooperates 
with the medical suggestions he or she has been provided” (Kao & Liu, 2010, p. 557), a 
definition consistent with the one used at the UCLA Aftercare Research Program (Kampman & 
Lehtinen, 1990). 
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Prevalence of Medication Nonadherence  
Estimates of the rate of medication nonadherence among individuals with schizophrenia 
range from 4-89%, and on average medication adherence is only around 50%  (Fleischhacker, 
Oehl, & Hummer, 2003; Lacro, Dunn, Dolder, Leckband, & Jeste, 2002). Many studies have 
reported differing levels of nonadherence, depending on the stage of the course of illness. Within 
the first psychiatric admission, up to 50% of individuals will be non-adherent to psychiatric 
medications (Verdoux et al., 2000), and one-third of patients will be medication non-adherent 
within six months of their first psychotic episode (Kamali et al., 2006). Some studies have found 
that within the first year of treatment 26-53% of patients in early psychosis terminate treatment, 
and within 1-2 years of follow-up, medication nonadherence rates are estimated to be 40% or 
more (Fenton, Blyer, & Heinssen, 1997; Steger et al., 2012). However, Steger et al. (2012) 
reported 33-63% of the participants with schizophrenia displayed inadequate levels of adherence. 
Data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) clinical trials 
for chronic schizophrenia, a benchmark study in the field of schizophrenia, found that 74% of 
participants discontinued medication during the 18-month trial (Lieberman et al., 2005). The 
CATIE study was pivotal for the field of schizophrenia research in many ways. It was a study 
sponsored by the National Institute of Mental Health and involved three phases using 1,460 
patients compiled from 57 sites in 24 states within the United States (Nasrallah, 2007). Many 
aspects of the studies were innovative for the time, most notably assessing the effectiveness of 
antipsychotic medications by measuring the time until medication discontinuation or switch in 
medication as the primary outcome (Weiden, 2007).  
The variability in the rate of medication nonadherence may be attributable to the 
naturally fluctuating nature of medication adherence over time, as well as differing definitions of 
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and methods to assess this phenomenon (Lacro et al., 2002).  Such variability notwithstanding, 
medication nonadherence remains a significant clinical issue in the treatment of schizophrenia. 
The costs of nonadherence, in terms of factors such as rehospitalization due to increased 
symptoms and associated impairment, has been estimated range from $106 million to $1,400 
million per year in the United States alone (Dilla, Ciudad, & Alvarez, 2013). Despite 
improvements in the science of antipsychotic medication, such as the abovementioned increased 
effectiveness and decreased side effects of the second generation antipsychotics, such 
advancements will be in vain if patients do not take them (Beck, Cavelti, Wirtz, Kossowsky, & 
Vauth, 2010; Leo et al., 2005). Little is known about why medication nonadherence is so 
prevalent in routine clinical practice, although research exploring the causes of nonadherence has 
significantly increased over the past two decades (Baloush-Klienman et al., 2011). Essentially, 
despite the varying numbers of medication adherence across dozens of studies, the trend across 
all of the findings is that medication nonadherence is unacceptably high in the treatment of 
schizophrenia, and due to the considerable detrimental consequences of nonadherence, more 
information needs to be gathered to help navigate productive changes in treatment. 
Effects of Medication Nonadherence  
 As mentioned, medication nonadherence is a major risk factor for relapse and 
hospitalization for individuals with schizophrenia (Kao & Liu, 2010). There are many negative 
outcomes that have been linked to medication nonadherence, such as exacerbation of psychotic 
symptoms, increased clinic and emergency room visits, rehospitalization, greater impairment in 
daily functioning, and poorer quality of life (Baloush-Kleinman et al., 2011; Lacro et al., 2002). 
The costs of psychiatric hospitalizations for schizophrenia patients in the U.S. are estimated to 
be over $10 billion annually (Wu et al., 2005). 
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Predictors & Correlates of Poor Medication Adherence  
Medication nonadherence in schizophrenia is likely influenced by multiple factors and 
several correlates of poor medication adherence have been identified in the literature. These 
correlates vary depending upon where an individual is in the course of schizophrenia. For 
example, individuals with first episode psychosis who are consistently non-adherent with 
antipsychotic medication tend to have had better premorbid adjustment and neurocognitive 
functioning (Robinson, Woerner, Alvir, Goldman, & Lieberman, 1999). As mentioned 
previously, they also typically have a later onset of psychotic symptoms. This suggests that 
perhaps better functioning individuals are more likely to deny the need for ongoing treatment, 
including medication, related to their schizophrenia (Robinson et al., 1999).  
 Medication related factors. Some factors commonly found to have an association with 
medication nonadherence are related to the medication itself (Tattan & Creed, 2001). Possible 
medication-related reasons for nonadherence include being prescribed an ineffective dosage 
(either too much or too little), palatability, medication duration, or even complexity of 
medication regimen (Leo et al., 2005).  Also, individuals may have adverse side effects from 
medications, which subsequently may provoke nonadherence. Such adverse side effects might be 
caused by current medications, although they may even be caused by previous medications with 
which the patient had a negative experience (Kao & Liu, 2010; Leo et al., 2005). An individual’s 
level of subjective distress related to extrapyramidal side effects is also strongly correlated with 
inadequate medication adherence (Kao & Liu, 2010). 
Another medication related factor of nonadherence is the cost of care and the individual’s 
ease of access to health care providers, because when it is difficult to access a doctor for 
prescription refills, it is likely that nonadherence will follow (Velligan et al., 2009). Even depot 
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(injectable) medications do not ensure perfect medication adherence since an individual can fail 
to receive the injection at the prescribed time interval (Kane & Malhotra, 2003). 
 Mental illness related factors. There are also illness related factors associated with 
medication nonadherence (Tattan & Creed, 2001). For example, certain thought processes 
associated with schizophrenia, such as disorganized thinking, and baseline positive symptoms, 
have been associated with medication nonadherence (Leo et al., 2005; Novak-Grubic & Tavcar, 
2002). More positive symptoms of schizophrenia, particularly grandiosity, along with a higher 
number of total symptoms, are also correlated with medication nonadherence (Coldham et al., 
2002; Kamali et al., 2006; Novak-Grubic & Tavcar, 2002; Steger et al., 2012). Perhaps counter-
intuitively, despite initial adequate medication adherence, Steger et al. (2012) showed that 
oftentimes in schizophrenia, once symptoms resolve as a result of medication, adherence to 
medication decreases. One may hypothesize that this is because an individual may feel better, 
and no longer believe they need medication. Comorbidity (e.g., mood disorders and substance 
disorders) is also strongly correlated with medication nonadherence (Coldham et al., 2002; 
Steger et al., 2012). Substance abuse is a strong predictor of medication nonadherence in general; 
and Kamali et al. found that the presence of a substance use disorder predicted medication 
nonadherence at the six-month mark of treatment (Kamali et al., 2006).  
There is a significant correlation between medication compliance and the duration of time 
an individual has been on psychotropic medications, specifically, the shorter the length of time 
the individual has been on medication, the less likely they are to be adherent (Tattan & Creed, 
2001). In other words,  
Patients who were poorly compliant did seem to have had a shorter, more severe course 
of illness with greater severity of negative symptoms and the same number of hospital 
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admissions in a shorter period of time compared with patients who were more compliant. 
(Tattan & Creed, 2001, p. 153) 
 Individual related factors. The presence of cognitive impairment is related to 
medication adherence because attention and memory deficits may impact an individual’s ability 
to develop a medication routine (Kozuki & Schepp, 2005; Lacro et al., 2002; Leo et al., 2005). In 
addition, an individual’s beliefs about the risks and benefits of medication, and how such beliefs 
may align with personal values and goals, may directly and poorly impact medication adherence 
(Leo et al., 2005). For example, if an individual believes that the risks of medication outweighed 
the benefits, he or she may be less willing to take medication. Or if an individual has particular 
cultural beliefs regarding the use of medication, such as believing homeopathic remedies should 
be utilized instead of prescription medication, medication adherence would also be adversely 
impacted.  
Insight into having a mental illness is also correlated to medication adherence (Buckley et 
al., 2007). If an individual is aware of and accepts having schizophrenia, and is able to recognize 
and label their symptoms, they will likely have a more positive attitude toward treatment, 
subsequently increasing the probability of medication adherence (Kao & Liu, 2010). A major 
factor that has been shown to hinder medication adherence is poor insight, as 50% of individuals 
with schizophrenia lack insight into their illness (Coldham at al., 2002; Kamali et al., 2006; 
Novak-Grubic & Tavcar, 2002).  
Personality characteristics, stigma associated with having schizophrenia, and personal 
priorities (such as wanting to have a sex drive and stopping medication because of its often 
negative effects on libido), are all more examples of individual-related factors associated with 
medication nonadherence (Kao & Liu, 2010; Leo et al., 2005). An individual’s beliefs regarding 
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the effectiveness of medication, the importance of treatment, and the significance of adherence, 
are also directly related to medication adherence (Kao & Liu, 2010; Steger et al., 2012; Velligan 
et al., 2009). Additionally those with less education, of younger age, and male gender are more 
likely to be medication non-adherent (Coldham et al., 2002; Kao & Liu, 2010; Steger et al., 
2012). 
Physician & treatment related factors. Sometimes, physician or treatment team related 
factors can negatively impact an individual’s medication adherence (Lacro et al., 2002; Tattan & 
Creed, 2001). Physicians who do not give the optimal dosage for treatment of schizophrenia, or 
physicians who do not provide patients with adequate medication psychoeducation regarding the 
role of medication in treating their illness, can undermine patient adherence (Leo et al., 2005). 
Also, sometimes medication nonadherence is increased because physicians do not tell their 
patients their diagnosis or medication schedule (Leo et al., 2005). 
 Leo et al. (2005) also identify the role patient and physician communication may play in 
impacting overall medication adherence. Compatible communication styles and strong rapport or 
alliance, are likely to improve adherence, whereas with less rapport the individual may be more 
likely to abandon treatment (Leo et al., 2005; Velligan et al., 2009). If a patient perceives that 
their clinician is genuinely interested in their wellbeing, and willing to dedicate time to their 
treatment, medication adherence is likely to be better. In contrast, nonadherence may result from 
a patient fearing abandonment by their physician if their symptoms improve (i.e., wondering if 
their doctor will discharge them). Nonadherence may also serve as a way to express discontent, 
frustration, or anger with treatment or the physician or treatment team (Leo et al., 2005). 
 Social & environmental factors. Lastly, social and environmental factors may play a 
significant role in medication adherence for individuals with schizophrenia (Leo et al., 2005; 
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Tattan & Creed, 2001).  Social and family support and involvement have been shown to increase 
medication adherence for individuals with schizophrenia (Coldham et al., 2002; Kao & Liu, 
2010; Velligan et al., 2009). When a person with schizophrenia lives with other people, 
medication adherence is generally better than when an individual lives independently because of 
the structure and support provided (Leo et al., 2005). Financial factors and access to treatment 
may hinder medication nonadherence (Kozuki & Schepp, 2005). For example, medication 
nonadherence likely would be greater when an individual has limited financial resources, is 
facing prohibitive medication costs, or has transportation difficulties limiting access to 
pharmacies or healthcare providers.  
Consequences of Poor Medication Adherence  
Among the significant negative consequences of medication nonadherence in 
schizophrenia are higher relapse rates and more frequent and longer hospitalizations (Tattan & 
Creed, 2001), which in turn are associated with increased care costs (Leo et al., 2005; Morken, 
Widen, Grawe, 2008). In particular, there is a correlation between medication nonadherence   
and violence perpetuated by psychotic individuals (Alia-Klein, O’Rourke, Goldstein, & 
Malaspina, 2007). Medication nonadherence can also have a significantly negative impact on 
academic and occupational functioning, social adaptation, and long-term functional adaptation 
(Leo et al., 2005). Patients with more prominent negative symptoms who are medication non-
adherent typically have a worse course of illness and poor prognostic outcome (Morken et al., 
2008). 
Relationship Between Negative Symptoms & Medication Adherence  
The research exploring the relationship between negative symptoms and medication is 
mixed and limited. It has been shown that having the ability to manage a medication regimen is 
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“at best a weak and non-specific correlate” (Heinrichs, Goldberg, Miles, & McDermid, 2008, p. 
50) with the presence of negative symptoms, suggesting that, if negative symptoms are 
associated with poor medication adherence, it is not because the negative symptoms limit an 
individual’s capacity to manage their medication. As mentioned, research indicates that having 
insight into having schizophrenia is negatively correlated with the presence of negative 
symptoms (Chang et al., 2011; Mintz, Dobson, & Romney, 2003). As such, there may be a 
relationship between insight and negative symptoms, and their conjoined impact on medication 
adherence. Due to minimal insight regarding the benefits of medication on symptom remission, 
the preventative effect of antipsychotics does not enhance medication adherence in those with 
significant negative symptoms (Beck et al., 2011). Such studies also indicate that the lack of 
insight regarding the benefits of medication and the steps needed for symptom remission are 
related to the high cognitive disorganization and anticipatory anhedonia associated with negative 
symptoms. In other words, negative symptoms may serve a moderating role in the impact of 
insight on medication adherence. 
As of now, there appear to be five studies with significant findings regarding a 
relationship between medication adherence and negative symptoms. Each study will be described 
in terms of setting, sample, measures, and findings:  
 Tattan & Creed published a study in 2001 exploring the relationship between negative 
symptoms and medication adherence in 58 individuals attending a depot clinic in Withington 
Hospital, South Manchester. Tattan and Creed stated that their purpose for the study was because 
a “possible association between negative symptoms of schizophrenia and compliance with 
medication has not been studied methodically” (p. 150).  They elaborated that although it may 
seem common sense to believe that individuals who experience negative symptoms would have 
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better medication adherence than those with positive symptoms because they may lack “assertion 
of will” (p. 150) that is not the case. Tattan and Creed hypothesized that negative symptoms 
would be related to poorer medication compliance because of potential lethargy and lack of 
motivation associated with negative symptoms. For the individuals in the sample, the duration of 
the illness averaged from 9 – 22 years, and individuals in the study were required to attend the 
clinic for at least the preceding year to be included in the study. Medication adherence was 
measured for one year by means of depot prescription cards and was rated in terms of good 
(complete compliance), intermediate (missed no more than one month of injections), and poor 
(medication missed for more than one month). The study instruments used were a clinical 
interview, convenience questionnaire (assessing convenience to clinic), Mini Mental Status 
Examination (assessing cognitive impairment), and the Scale for Assessment of Negative 
Symptoms (SANS; to assess the presence and severity of negative symptoms). Upon analyses of 
the results, the individuals in the study who fell in the poor compliance group had significantly 
higher SANS scores for avolition, apathy, and alogia (Tattan & Creed, 2001). Additionally, the 
overall SANS score was higher for individuals with poor compliance. Another finding was that 
the individuals who were poorly compliant appeared to have a shorter, more severe, course of 
illness with greater severity of negative symptoms. The authors recognized that one of the 
limitations of their study was that the sample did not include individuals who were completely 
nonadherent to medication. 
In 2010, Kao and Liu published a study exploring the variables associated with 
antipsychotic treatment in those with schizophrenia. They hypothesized that medication 
adherence would be positively associated with insight and negatively correlated with symptoms 
and side effects of medication. The sample included 113 participants who had been diagnosed 
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with schizophrenia for longer than one year. All 113 participants were receiving antipsychotic 
medication treatment prior to the start of the study.  The study instruments were the Medication 
Adherence Rating Scale (MARS), Self-Appraisal of Illness Questionnaire (SAIQ), Positive and 
Negative Syndrome Scale (PANSS), Extrapyramidal Symptoms Rating Scale (ESRS), Beck 
Depression Inventory, Beck Hopelessness Scale, Scale for Suicide Ideation, Anxiety Checklist, 
and the Global Assessment of Functioning (GAF). The study found that subjective response to 
medication and medication adherence are the two factors influencing medication adherence.  The 
study shared many findings related to the role of insight in medication adherence and indicated 
that medication adherence was significantly predictive by the positive component of the PANSS, 
depressive symptoms, outcome of illness, and severity of extrapyramidal side effects. Kao and 
Lui also found that the presence of negative components of Kay, Flazbein, and Opler’s (1987) 
Positive and Negative Syndrome Scale (PANSS) was statistically significantly related to MARS 
scores assessing medication nonadherence, in that the negative symptom components of the 
PANSS were positively correlated with medication nonadherence.  
Baloush-Kleinman and colleagues published a study in 2011 exploring the usefulness of 
the Health Belief Model in explaining antipsychotic medication nonadherence in early 
schizophrenia. The study included 112 individuals who were earlier in the course of their illness, 
but were not in their first psychotic episode. Medication adherence was assessed with the Visual 
Analog Scale for Assessing Treatment Adherence, and symptom severity was assessed with the 
Clinical Global Impression. The Scale for the Assessment of Negative Symptoms (SANS) and 
the Scale for the Assessment of Positive Symptoms (SAPS) were also administered to assess 
severity of positive and negative symptoms. The Cognitive Appraisal of Health Scale and Scale 
to Assess Unawareness of Mental Disorder were administered to assess health beliefs and insight 
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into their psychotic illness, respectively.  The MacArthur Competence Assessment Tool, 
Extrapyramidal Symptom Rating Scale, Liverpool University Neuroleptic Side Effect Rating 
Scale, Drug Attitude Inventory, and Trust in Physician Scale were also administered. The results 
suggested that in comparison to partially or completely nonadherent individuals, medication 
adherent individuals have increased insight into their illness and the need for treatment, and more 
awareness of the illness’ social consequences. Additionally, adherent individuals appeared to 
have more positive views of their doctor-patient alliance, and had families with more positive 
attitudes towards medication. Interestingly, Baloush-Kleinman et al. found that negative 
symptoms did not directly impact, but rather indirectly impacted medication adherence. 
Specifically, by means of structural equation modeling, they found that the presence of negative 
symptoms predicted attitudes (related to insight, medication costs, and medication benefits) 
towards medication, which then in turn predicted adherence.  
In 2012, Steger et al. published a study exploring symptom resolution’s impact on 
medication adherence in first episode psychosis. Given that the sample for the study was a first 
episode psychosis population, the authors hypothesized that rapid symptom improvement would 
be associated with subsequent medication adherence. Participants in the study were recruited 
from the Prevention and Early Intervention in Psychosis Program in Montreal (PEPP-Montreal) 
in Quebec, Canada. The 216 participants did not have more than one-month exposure to and 
treatment with antipsychotic medication prior to the start of the study. The study instruments 
were the Scale for Assessment of Positive Symptoms (SAPS), Scale for Assessment of Negative 
Symptoms (SANS), Calgary Depression Scale for Depression in Schizophrenia, Barnes 
Akathisia Scale, and the Extrapyramidal Symptom Rating Scale. Medication adherence was 
determined based on client and case manager report and pill counts. Adherence was converted to 
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a percentage and categorized as: Never Adherent (0%), Very Infrequently Adherent (1-25%), 
Sometimes Adherent (26-50%), Quite Often Adherent (51-75%), or Always Adherent (>75%). 
Any adherence less than 75% was deemed “inadequate” (p. 46). The authors found that at the 
three-month mark of the study most participants whose negative symptoms had resolved also had 
lower levels of positive symptoms. At the six-month mark there were even a greater number of 
participants with resolved negative symptoms than at the three-month mark. Another finding was 
that early resolution of negative symptoms was associated with less adequate adherence, whereas 
those whose negative symptoms persisted were more likely to be adherent to their medication 
regimen. Steger at al. found that individuals whose negative symptoms had resolved after three 
months were less likely to have adequate adherence at six months. This may be due to the 
individual’s belief that a substantial improvement in symptoms may indicate readiness to stop 
taking medication. This effect may also be due to the fact that negative symptoms often cause 
significant functional impairment. Therefore, one may believe that negative symptom reduction 
is associated with returning to normal functioning, consequently deciding that medication is no 
longer needed (Quach et al., 2009; Steger et al., 2012).  Of the participants who had early 
resolution of negative symptoms, the ones who were adequately adherent were compared with 
those who were inadequately adherent. The comparison revealed that there was a greater 
presence of alogia and affective flattening in medication nonadherent individuals (Steger et al., 
2012). Further analyses explored whether the reduction in negative symptoms was due to a 
reduction in parkinsonian side effects associated with ceasing medication, and the authors 
determined this was not a significant factor. 
Subotnik et al. published a study in 2014 exploring the extent to which the severity of 
initial positive and negative symptoms is related to medication nonadherence in individuals with 
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recent-onset schizophrenia. The sample consisted of 66 individuals all of whom experienced 
their first major psychotic episode within two years of the study entry. The study instruments 
were the Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for the 
Assessment of Negative Symptoms (SANS). Medication adherence ratings were on a scale from 
1 to 5, with lower scores indicating nonadherence and higher scores indicating better adherence. 
The medication adherence rating was determined based on data collected from pill counts, 
plasma concentrations, patient report, clinician assessment, and the Medication Event 
Monitoring System (MEMS-6). The study spanned 12 months and data analyses explored the 
relationship between symptoms and medication adherence in addition to whether there was a 
temporal relationship between the two variables in order to infer causality. It appears that this is 
the only prior study exploring a potential temporal relationship between negative symptoms and 
medication adherence. The results suggested that higher levels of medication adherence were 
generally associated with lower levels of reality distortion. Lower levels of avolition-apathy and 
alogia were associated with better medication adherence during the three-month baseline 
interval. Data analyses exploring potential causality suggested that there is a causal relationship 
between initial medication adherence and lower levels of alogia. While this study revealed that 
adherence to medication led to lower negative symptoms, it appeared that this relationship was 
mediated by a reduction in positive symptoms.  
Statement of Problem 
Individuals with schizophrenia who have more prominent negative symptoms typically 
have a poor prognostic outcome compared to those without such symptoms.  Although little 
research has looked at the relationship between medication adherence and negative symptoms of 
schizophrenia, the few critical findings have been described above.  It appears that current 
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antipsychotic medications are only minimally effective in treating negative symptoms. 
Furthermore, current research suggests that individuals with schizophrenia with significant 
negative symptoms have poorer medication adherence than those who do not have negative 
symptoms of schizophrenia. Many studies appear to have high attrition rates, and it is likely that 
patients who have missing data in studies or drop out of studies are nonadherent with medication 
and typically do not show up for end of study evaluations (Steger et al., 2012). Related to 
negative symptoms, Steger et al. (2012) found that individuals whose negative symptoms had 
resolved by the three-month mark of the study, were subsequently more likely to have missing 
data at the six-month mark. Additionally, the effect of subjects withdrawing from studies and the 
effect of missing data in studies on overall findings related to medication adherence in 
schizophrenia is unknown, thus there are potentially still many gaps in the literature.  Since 
medication adherence has consistently been found to be predictive of better outcomes, it is 
critical that this area is further explored.  
Significance of Proposed Study  
Medication nonadherence is perhaps the single most preventable cause of psychotic 
relapse in schizophrenia. Intuitively, negative symptoms would appear to lead to medication 
nonadherence, but the very few studies that have empirically examined this question did not 
consistently observe this relationship. Identification of predictors of medication nonadherence 
might lead to useful interventions that could have a huge public health significance.  This study 
will gain more information about a potentially causal relationship between negative symptoms 
and medication adherence.  
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Research Question 
Exploring the relationship between medication adherence and negative symptoms could 
have significant consequences for treatment interventions. This study will primarily be exploring 
the question: is the presence of negative symptoms in schizophrenia related to decreased 
medication adherence? The temporal relationship of negative symptoms and medication 
nonadherence will be examined for the appearance of a causal relationship between the two. It is 
hypothesized that the presence of negative symptoms is a primary contributing factor in 
decreased medication adherence.  
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Chapter 2:  Methodology 
Participants 
 The study sample was gathered from participants receiving treatment for first-episode 
psychosis at the UCLA Aftercare Research program. The sample consists of 148 individuals who 
qualified as being in the midst of their first psychotic episode, meaning individuals within the 
first two years of their first psychotic episode. All participants were followed clinically at the 
UCLA Aftercare Research Program and received outpatient psychiatric treatment as part of 
studies sponsored by NIMH grants MH37705 and MH66286 to K. Nuechterlein, Ph.D., P.I. 
(ClinicalTrials.gov identifiers NCT00203788 and NCT00333177). Treatment included regular 
psychiatrist visits, antipsychotic medication, and individual case management and therapy by 
Master’s and Doctoral level therapists. The second-generation antipsychotic medication, 
risperidone, was used as the first line medication to stabilize participants at baseline (provided by 
Janssen Scientific Affairs, Janssen RIS-SA-67 and RIS-NAP-4009). The program was the 
participant’s primary source of mental health treatment, and typically involved 1-2 clinic visits 
per week.  
   Participants at the UCLA Aftercare Research Program were recruited from a variety of 
settings including Los Angeles area psychiatric hospitals and clinics, and the UCLA outpatient 
service at the Resnick Neuropsychiatric Hospital at UCLA. The analysis examined the period 
beginning at outpatient stabilization and covered the subsequent 12 months or until the 
medication trial was terminated due to a switch of the primary antipsychotic medication or 
withdraw from the study.  The participants were not recruited or referred to the program based 
on previous level of medication adherence. Participants provided written informed consent and 
were given both oral and written information about the research procedures prior to receiving 
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services from the program. The UCLA Institutional Review Board approved both longitudinal 
protocols. 
In order to meet criteria for the UCLA Aftercare Research Program, and be included in 
this sample, participants (a) were within two years of the onset of their first major psychotic 
episode; (b) had a diagnosis of schizophrenia or schizoaffective disorder, mainly schizophrenic 
subtype, based on the Research Diagnostic Criteria (RDC; Sample 3), or Schizophrenia, 
Schizophreniform, or Schizoaffective Disorder, Depressed Type (DSM-IV, for Sample 4); (c) 
were between the ages of 18 and 45 years; (d) had no evidence of a known neurological disorder; 
(e) had no evidence of significant and habitual illicit substance abuse or alcoholism in the six 
months prior to admission to the program, no evidence that substance use accounted for the 
psychosis, and no evidence that substance use would be a prominent factor in the course of 
illness; (f) had no premorbid mental retardation; (g) had sufficient acculturation and English 
language fluency to avoid invalidating research measures of symptomology;  (h) lived within 
commuting distance of the UCLA Aftercare Program; and (i) did not have a contraindication for 
risperidone (e.g., allergic reaction, intolerable side effects experienced in a previous trial, failed 
trial that was of sufficient length and in which patient was considered adherent), the initial 
standardized antipsychotic medication used in the study.   
The sample of this dissertation study consisted of 148 individuals: 65 individuals in 
Sample 3, and 83 individuals in Sample 4, all of whom have had schizophrenia and the onset of 
their illness was within two years of study entry. Both samples were a part of an NIMH-funded 
project entitled, “Developmental Processes in Schizophrenic Disorders,” with Sample 3 
participants also enrolled in a study called, “Improving and Predicting Work Outcome in Recent-
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Onset Schizophrenia,” and Sample 4 participants enrolled in a study called, “Cognitive 
Remediation, Medication Adherence, and Work Outcome in Recent-Onset Schizophrenia.”  
Design 
This study involves exploratory analyses of previously collected data as part of a larger 
study. Once admitted to the UCLA Aftercare Research Program, participants were stabilized on 
oral risperidone, an FDA approved second-generation antipsychotic medication and randomized 
to an intervention.  One sample, that will be referred to as Sample 3, consisted of an 18-month 
study comparing two psychosocial interventions to which patients were randomly assigned: an 
Individual Placement and Support (IPS) and Workplace Fundamentals Module intervention 
condition, or a Brokered Vocational Rehabilitation condition (consisting of vocational 
rehabilitation through referral to outside agencies). The details of the two psychosocial 
interventions are provided elsewhere (Subotnik et al., 2011; Subotnik et al., 2015), as this study 
is focusing on medication adherence and negative symptoms specifically, within the greater 
study. The other sample, which will be referred to as Sample 4, participated in a 12-month study 
comparing long-acting injectable risperidone to oral risperidone. Each participant began the 
study with oral risperidone as the only antipsychotic medication for a minimum of three weeks. 
Subsequently, participants were randomized to either continued oral risperidone treatment or the 
long-acting injectable form of risperidone (RLAI). To maintain comparability, this study will 
only examine data from those in Sample 4 who were randomized to the oral risperidone group. 
Sample 4 participants were also randomized to either a cognitive remediation or healthy lifestyle 
skills training as part of a fully crossed 2x2 design. For a summary of the psychosocial 
interventions see Subotnik et al. (2015). Additionally, as Sample 3 was of longer duration than 
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Sample 4, for consistency the present study will only be examining data from the first 12 months 
of adherence and symptom data from all participants.  
Institutional Review Board (IRB) approval. The original UCLA Aftercare Research 
Program studies from which data were used for this dissertation received full IRB approval from 
UCLA. This author also received approval for IRB exemption from the Pepperdine University 
Graduate and Professional Schools IRB (GPS IRB) because this study used archived, de-
identified data (see Appendix A). Lastly, this author obtained permission from the UCLA 
Aftercare Research Program to use their de-identified, archived data for this dissertation (see 
Appendix B). 
Measures 
Medication adherence. Medication adherence was assessed by considering a variety of 
factors and developing a numerical value to represent level of adherence to prescribed 
medication. Each factor comprising medication adherence was categorized and rated to evaluate 
the level of medication adherence for each two-week interval of time. The factors, or source of 
information, comprising medication adherence were: pill counts (typically assessed bi-weekly); 
plasma concentrations of risperidone and 9-hydroxyrisperidone (nonadherence was flagged by 
nondetectable levels of 9-hydroxyrisperidone; typically assessed every 4 weeks); self-report of 
nonadherence to a member of the treatment team (typically assessed every 1 to 2 weeks); 
assessment by a clinician based on occurrence of side effects (typically assessed every 1 to 2 
weeks); and Medication Event Monitoring System (MEMS-6®, Sample 4 only). The Medication 
Event Monitoring System is a medication bottle whereby the lid electronically tracks the date 
and time that the bottle has been opened and closed since the last time the cap was monitored. 
Adherence ratings were made on a bi-weekly basis even when all sources of information were 
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not available during a rating period. Each participant’s medication adherence was rated on a 1 - 5 
scale, with one representing perfect adherence (100%) and 5 representing lowest adherence 
(0%). Medication adherence ratings also consist of the rater identifying his or her level of 
confidence in the accuracy of their rating (on a scale of 1 to 5, with 1 = very little confidence and 
5 = very confident). Each patient’s weekly medication adherence ratings were then averaged into 
one-month, as well as 3-month interval ratings.  Patient participants in Sample 4 who were 
randomly assigned to long-acting injectable medication were excluded from these analyses 
because the level of adherence tended to be nearly perfect across patients and across time points, 
which would preclude analyses of temporal relationships among adherence and symptoms 
measures.  Further, the long-acting nature of the injectable medication would hamper the 
examination of the relationship of short-term changes in adherence and symptoms.  
Symptom assessment. Symptoms were assessed by trained raters administering 
measures beginning at study entry and throughout the longitudinal treatment and assessment 
follow-through period.  
 Brief Psychiatric Rating Scale (BPRS). Psychiatric symptoms were assessed using the 
expanded 24-item version of the Brief Psychiatric Rating Scale, which is semi-structured and 
requires self-report and clinician observation to establish ratings (see Appendix C; BPRS 
Version 4.0; Overall & Gorham, 2008; Ventura et al., 1993). The BPRS was created by John E. 
Overall and Donald R. Gorham in 1962 and is a clinician-rated measure designed to provide a 
comprehensive description of significant symptom characteristics in individuals with psychotic 
illnesses (Overall & Gorham, 2008; Ventura et al., 1993). The expanded version was created in 
1993 by the Clinical Research Center for Schizophrenia and Psychiatric Rehabilitation, UCLA 
Department of Psychiatry and Biobehavioral Sciences, and the West Los Angeles VA Medical 
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Center (Ventura et al., 1993). The expanded version includes six new scales for more 
comprehensive assessment of serious mental illness symptoms, and allows for multiple sources 
of information, such as from the patient, parents or relatives, mental health professionals, 
medical chart, or other sources – such as police reports (Ventura et al., 1993). The BPRS 
specifically monitors symptom frequency and severity, and each item is rated from 1 - 7 (1 = not 
present, 7 = extremely severe; see Appendix C for scoring record form). Although the manual 
has descriptions for each anchor point, for specific examples that are not included in the anchor 
points, the scoring system essentially can be understood as ratings of 2 - 3 representing 
nonpathological, yet mild and observable symptomatology; ratings of 4 - 5 representing 
moderate and clinically significant symptomatology; and ratings of 6 - 7 representing the 
presence of severe and clinically significant symptomatology (Ventura et al., 1993). Symptoms 
rated in the severe range (6 - 7) typically represent pathological experiences. The BPRS typically 
takes 20-30 minutes to administer, with the first 14 items of the measure rated based on the 
patient’s self-report, and the last 10 items rated based on observed behavior or speech of the 
patient during the interview (Overall & Gorham, 2008; Ventura et al., 1993). 
The BPRS was administered at the point of outpatient medication stabilization, every two 
weeks during the first year of enrollment in the UCLA Aftercare Research Program. The raters 
for the BPRS all participated in a quality assurance program and achieved a median Intraclass 
Correlation Coefficient (ICC) of .80 or higher across all items compared with the criterion 
ratings (Ventura et al., 1993). Means of one-month intervals of BPRS ratings were established, 
which constitute the BPRS data that will be used in this report. Further, for the purpose of this 
study (to address negative symptoms specifically), items related to self-neglect, blunted affect, 
emotional withdrawal, motor retardation will be of primary focus.  
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The Self- Neglect scale of the BPRS Version 4.0 assesses level of hygiene, grooming, 
and meeting basic needs (i.e., showering and eating) to determine whether such behaviors are at 
an acceptable level based on socially acceptable standards (Ventura et al., 1993). This relates to 
the negative symptom, avolition. The BPRS Version 4.0 scale Blunted Affect pertains to the 
patient’s range of emotional expressiveness of their face, voice, or gestures. The more restricted 
the affect, the higher the rating. A blunted affect may also manifest in marked indifference or 
flatness when discussing upsetting or stressful topics. Oftentimes, blunted affect is referred to as 
affective flattening. The Emotional Withdrawal scale assesses the patient’s capacity to relate 
emotionally to the interviewer during the assessment. The more deficient an individual’s ability 
is to relate emotionally, the higher the rating on the scale. The BPRS scale Motor Retardation 
assesses the negative symptom of anergia. This scale evaluates the patient’s energy level, 
specifically whether there is a reduction in energy level, which is often evidenced by slowed 
movements and speech, reduced body tone, and decreased frequency of spontaneous body 
movements. 
With substantial time and effort, good interrater reliability can be achieved with the 
BPRS (ICC > 0.80; Overall & Gorham, 2008). It is typically more difficult to receive higher 
levels on interrater reliability on observational items than on items requiring the patient’s self-
report (Overall & Gorham, 2008). Additionally, the detailed anchor descriptors often aid in 
increasing interrater reliability. The BPRS also has good internal consistency for positive and 
negative symptoms (Cronbach α = 0.81, 0.91, respectively; Overall & Gorham, 2008). The 
BPRS has good validity when compared to other symptom measures for general 
psychopathology, such as the SANS, SAPS, and PANSS (Overall & Gorham, 2008). The BPRS 
is correlated with scales on both the SANS, and SAPS (r = 0.63), as well as the positive, 
	   32 
negative, and total symptom scales of the PANSS (r = 0.92, 0.82, 0.84, respectively; Overall & 
Gorham, 2008). Overall, the BPRS is a sound instrument that has been extensively used dating 
back to the 1970s, and is commonly used in research studies (Overall & Gorham, 2008). 
 Scale for the Assessment of Negative Symptoms (SANS). The Scale for the Assessment 
of Negative Symptoms (SANS) is a 23-item measure used to assess the presence of the negative 
symptoms associated with psychotic disorders (see Appendix D). It is currently considered the 
gold standard for assessing the presence and severity of negative symptoms (Andreasen, 1983; 
Hanson et al., 2010). It takes approximately 30-minutes to administer and consists of five 
subscales: Affective Flattening or Blunting, Alogia, Avolition-Apathy, Anhedonia-Asociality, 
and Attentional Impairment (Andreasen, 2008). Affective Flattening is assessed by evaluating an 
individual’s affect, such as whether the individual has poor eye contact, inappropriate affect, 
unchanging social expression, minimal expressive gestures, and so forth (Andreasen, 2008). The 
Alogia category consists of whether an individual is demonstrating poverty of speech, thought 
blocking, or a long latency for responding in conversation. The Avolition-Apathy category is 
evaluated by assessing an individual’s grooming, hygiene and physical anergia. The Anhedonia-
Asociality category includes assessing an individual’s interest and activity level, ability to feel 
close and intimate with others, and quality and frequency of relationships with friends and 
others. Lastly, the Attention category includes whether the individual is socially attentive, and 
attentive during the testing of their mental status (Andreasen, 2008). The SANS is clinician rated 
based on all information available, including observation and reports from the previous month, 
which may limit the measure’s ability to detect rapid symptom changes (Hanson et al., 2010). 
Each subtest assesses specific behaviors, which are rated from 0 to 5 (0 = not present), and also 
has a Global Rating item evaluating categories of symptoms in general. In order to increase inter-
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rater reliability, each SANS rater achieved a median ICC of 0.75 or higher across all items 
compared with the criterion ratings, and participated in a quality assurance program. The SANS 
was administered to participants every three months.  
 Overall, there are mixed findings in the literature regarding the interrater reliability of 
SANS, ranging from fair to very good (ICC = 0.60 – 0.84; Andreasen, 2008). The interrater 
reliability of the five domains covered in the SANS ranges from 0.86 – 0.93, with the interrater 
reliability of the Total Score being 0.92 (Andreasen, 2008). The interrater reliability of the 
individual items on the SANS ranges from 0.70 to 0.92 (Andreasen, 2008). Findings suggest that 
the SANS has moderate test-retest reliability, with the Total Score test-retest reliability being 
0.45, and the test-retest of the different domains ranging from 0.13 – 0.40 (ICCs; Andreasen, 
2008). The modest test-retest reliability for the SANS is likely due to the nature of how symptom 
severity typically fluctuates within schizophrenia (Andreasen, 2008). The SANS has high 
internal consistency (Cronbach α = Alogia, 0.63; Affective Flattening, 0.83; Avolition-Apathy, 
0.74; Anhedonia-Asociality, 0.77; Attention, 0.75; Andreasen, 2008). Internal consistency is also 
high within the five domains of the SANS (Cronbach α = 0.86). Overall, given that the SANS is 
the gold-standard for assessing negative symptoms, is widely known and used, and has fair- to-
good psychometric properties, it is appropriate for use for assessing negative symptoms in this 
study. 
Procedures 
The UCLA Aftercare Research Program recruits its participants from a variety of local 
Los Angeles psychiatric hospitals and clinics. Additionally, participants were obtained through 
referrals from the UCLA outpatient service at the Resnick Neuropsychiatric Hospital at UCLA. 
Previous level of medication adherence was not a consideration when recruiting participants. As 
	   34 
this program was the participant’s primary source of mental health treatment, participant’s 
typically attended the clinic at least one time per week. All participants consented to oral and 
written information about the research procedures involved in this study, and provided written 
consent. Most participants entered the study after a psychiatric hospitalization, and at the time of 
study entry diagnostic, demographic, psychiatric, social history, and functional capacity data 
were collected for each participant. This study was reviewed and approved by the UCLA 
Institutional Review board. 
Data were collected in a variety of ways. Medication adherence was converted to a 
numerical value on a scale of 1 - 5, as previously mentioned, and utilized a number of sources of 
information to form a consensus rating of the level of adherence for every week of the follow-
through. In addition to confidence and overall compliance ratings, information was collected and 
documented related to the participant’s daily prescribed dose, number of milligrams consumed, 
changes in medication prescriptions, percentage of adherence, and reasons for missed doses.  
As mentioned above, the BPRS was administered bi-weekly and the SANS was 
administered every three months. 
Data Analysis Plan 
Descriptive analyses will be completed on the demographics of the sample. The primary 
data analysis of medication adherence and negative symptom data will involve Pearson 
correlations and repeated measures analysis of variance (ANOVA), specifically Generalized 
Linear Mixed Models (GLMM). The analyses will have three phases. Phase I will utilize Pearson 
correlations to assess the strength of the relationship between medication adherence and negative 
symptoms. Then bivariate correlations will be completed with time lags to explore a potential 
temporal relationship between negative symptoms and medication nonadherence. Phase II will 
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consist of a GLMM to examine how the strength of the relationship between medication 
adherence and negative symptoms changes when controlling for multiple observations within 
subjects. A GLMM will then analyze the temporal relationship between medication adherence 
and negative symptoms using time lags (similar to the Pearson correlations) but while controlling 
for multiple observations within subjects. The last phase of data analysis (Phase III) consists of 
using a GLMM with a mediational term to explore the impact of a third variable (Reality 
Distortion) mediating the potential relationship between negative symptoms and medication 
adherence. The three phases will examine data comprised into one-month intervals. Specifically, 
intervals of time were used rather than specific time-points during the course of the 12-month 
study. This data analyses plan was selected to order to determine the optimal temporal gap to 
examine the relationship between medication nonadherence and negative symptoms.  
Phase I: Pearson Correlations 
 The concept of Pearson correlations dates back to the 19th century, when Sir Francis 
Galton published an article in 1888 about the correlation; however, it adopted its name when 
Karl Pearson introduced the idea of correlation coefficients (Chen & Krauss, 2004). Pearson 
correlations, also referred to as Pearson product-moment correlations, refer to examining the 
strength of a linear relationship between two variables (Chen & Krauss, 2004).  The correlation 
is given a numerical value, ranging from 0 to 1, called the correlation coefficient (r), and the 
larger the number, the stronger the relationship between the two variables (Chen & Krauss, 
2004).  For the purposes of this study, Pearson correlations will be used to assess the significance 
of correlations between medication adherence and negative symptoms. Whether the coefficient is 
positive or negative, relates to the direction of the relationship (either positive, negative, or null). 
A positive coefficient means that an increase in one variable, is associated with an increase in the 
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other variable (or decrease in one variable is associated with a decrease in the other; Chen & 
Krauss, 2004). A negative coefficient means that an increase in one variable is associated with a 
decrease in the other variable (or a decrease in one variable is associated with an increase in the 
other variable; Chen & Krauss, 2004). A null relationship between the two variables indicates 
that an increase in one variable is associated with both an increase and decrease in the other, and 
vice versa (Chen & Krauss, 2004). 
 Pearson correlations will be deemed significant should the p-value equal less than or 
equal to 0.05 (p < 0.05). The p-value represents the probability of obtaining a test statistic at least 
as extreme as the correlation co-efficient (r) that was obtained (in the same direction) when the 
null-hypothesis is assumed to be true (Gibbons, 2004). It is important to note that Pearson’s 
correlation coefficients of greater magnitude and significance does not suggest causality between 
the two variables. For this study, Pearson correlations will initially be completed in Phase I to 
examine the strength of the overall relationship between negative symptoms and medication 
adherence. Then Pearson bivariate correlations will be completed with time lags to determine 
whether there is a temporal relationship between negative symptoms and medication adherence.  
For example, since data will be divided among one-month intervals, Pearson correlations will be 
completed to examine the strength of the relationship between medication adherence and 
subsequent negative symptoms one month later, two months later, and so on up to twelve months 
later. Reversely, Pearson correlations will be completed to examine the strength of the 
relationship between negative symptoms subsequent medication adherence one month later, two 
months later, etcetera, up to twelve months later. Bivariate correlations utilizing time lags will 
indicate the direction of a potential relationship between medication adherence and negative 
symptoms.  
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Phase II: A Generalized Linear Mixed Model (GLMM) 
Analysis of variance (ANOVA) is a type of statistical analyses used to detect differences 
between two or more groups on an independent variable with repeated measures for subjects 
(Witte & Witte, 2004). The Generalized Linear Mixed Model (GLMM) is a generalized form of 
ANOVA that is useful for controlling for multiple observations per subjects.  This form of 
analysis can easily accommodate missing data and is well suited for a longitudinal study such as 
this. In the current study, there are repeated measures of both negative symptoms and medication 
adherence over the course of twelve months (Witte & Witte, 2004). Repeated measures ANOVA 
is used when all participants comprising a sample are measured under multiple conditions (such 
as at multiple time points). As with ANOVA, the subject’s ratings are compared to their own 
ratings, and therefore key estimates of variability are not inflated by variability due to differences 
between individuals (Witte & Witte, 2004).  
The null hypothesis for GLMM is that the independent variable does not impact the 
dependent variable, and therefore the dependent variable will be similar despite differing values 
of the independent value. Whether or not the null hypothesis of an ANOVA is false depends on 
whether there is evidence of an effect of the independent variable. If the variability between 
groups (e.g., symptom ratings at different intervals of time) exceeds variability within groups 
(e.g., symptom ratings of different participants at the same interval of time) the null hypothesis 
can be rejected.  
The null hypothesis for the GLMM is tested by means of an F test. An F test refers to the 
F ratio, which is the variability between groups divided by the variability within groups (Witte & 
Witte, 2004). Specifically, the numerator is the observed differences between all sample means 
and the denominator is the estimated error or combined variance estimate (Witte & Witte, 2004). 
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The F test assumes that if the null hypothesis is actually true, both the numerator and the 
denominator of the F ratio will be approximately the same. If the null hypothesis is false, the 
numerator will be larger than the denominator. Therefore, if an F value is approximately (or less 
than) one, there is no significant association between the independent and dependent variable 
(e.g., no treatment effect). The larger the F value, the smaller the level of significance between 
the independent and dependent variable. F values will be deemed significant should the p-value 
equal less than or equal to 0.05 (p < 0.05). 
 For this study, Phase II will consist of completing GLMM analyses as a means of 
examining the strength of association between medication adherence and negative symptoms 
while controlling for multiple observations within subjects.  
Phase III: Generalized Linear Mixed Model (GLMM) including a Mediational Term 
In order to solidify the causality of the bivariate correlation and mixed model GLMM, the 
null-hypothesis should be explored, which suggests that the relationship between the independent 
variable (X) and dependent variable (Y) is not causal but rather due to an unmeasured third 
variable, a mediator, M (Kenny, 1975). Without testing for mediating variables, variable X is 
considered the causal variable that causes the outcome (Y). The path from the independent 
variable to the dependent variable (X to Y) is called the total effect (C; see Figure 1). However, it 
is possible that there is third variable, or mediating variable (M) that is affecting Y, initially 
making the impact of X on Y appear stronger than it is in actuality.  
 
                                                                          C 
                                        X                                        Y 
 
Figure 1. Description of a causal relationship between an independent (X) and dependent 
variable (Y). 
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For the current analyses, the mediation effect will be estimated through the inclusion of 
the mediating variable in the GLMM analyses and by estimating c’ and comparing this parameter 
estimate with an estimate of c.  In Subotnik et al. (2014), it was observed that the relationships 
between antipsychotic medication adherence on negative symptoms in this same sample was 
mediated by the effect of medication adherence on positive symptoms, which subsequently led to 
improvement in negative symptoms. This potential mediation process will be explored in the 
current sample, utilizing much short time periods for assessing both adherence and negative 
symptoms.  Thus the GLMM will analyze whether X causes Y, or rather whether M is an 
intervening variable and thus X has a significant relationship to M, and M has a significant 
relationship with Y (see Figure 2; Kenny, 2014). Should the independent variable no longer 
affect the dependent variable once the mediator has been controlled for, then it is called complete 
mediation and the mediating variable is solely causing the significant relationship observed 
between the independent and dependent variables (in which case c’ would be zero). If when 
controlling for M the direct effect (c’) is reduced in size (but not zero), i.e. c’ < c then partial 
mediation is occurring. 
 
 
                                                M 
 
                                                    a                         b        
 
                                                 c’ 
                                        X                                        Y 
 
Figure 2. Demonstration of the role of mediating variables (M) in the impact of the independent 
variable (X) on the dependent variable (Y). 
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Chapter 3: Results 
As stated in Chapter 1, the study reported here examined the relationship between 
medication adherence and negative symptoms of schizophrenia in first episode psychosis. This 
chapter is organized in terms of the three phases of data analyses listed in Chapter 2. It reports 
the (a) characteristics of the study sample, (b) the relationship between negative symptoms and 
medication adherence using bivariate correlational methods that specifically examine different 
time lags between the measurements of adherence and symptoms, (c) a mixed model ANOVA 
(GLMM) approach that will examine the relationships between medication adherence and 
negative symptoms while controlling for multiple observations within subjects, and (d) a mixed 
model ANOVA (GLMM) approach that will examine the relationships between medication 
adherence and negative symptoms controlling for reality distortion, which is a likely third 
variable that could potentially mediate the main relationships.  
Characteristics of the Study Sample 
The study sample consisted of a total of 148 participants: 65 Sample 3 participants, and 
83 Sample 4 participants.  All had been diagnosed with either schizophrenia, schizoaffective 
disorder, or schizophreniform, according to the DSM-IV (demographics provided in Table 1). To 
be included in the sample, the onset of their illness was within two years of study entry. The 
gender of the sample (combined Sample 3 and Sample 4) participants was as follows: 73% male 
(n = 108) and 27% female (n = 40; see Table 1). The mean age of the sample was 22.5 years, 
with a standard deviation of 4.0. In terms of race, 48% (n = 71) of the sample participants 
described themselves as Caucasian; 25% (n = 37) described themselves as African American; 
11% (n = 16) described themselves as Asian; 2% (n = 3) described themselves as Pacific 
Islander; 3% (n = 5) described themselves as American Indian/Alaskan; 11% (n = 16) described 
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themselves as Biracial or Multiracial (Mixed). 42% of the sample (n = 62) had a Hispanic 
ethnicity. The mean level of education was 12.8 years, with a standard deviation of 1.9. 
Additionally, in terms of marital status, 95% (n = 141) of the sample was single, 4% (n = 6) were 
married, and 1% (n = 1) were separated. The average time since onset of first psychotic episode 
at the initial point of the study was 8.0 months, with a standard deviation of 8.6. Regarding 
diagnosis, 59% (n = 87) were diagnosed with Schizophrenia, 14% (n = 21) were diagnosed with 
Schizoaffective Disorder, and 27% (n = 40) were diagnosed with Schizophreniform.  
The 12 months of data analyzed for this study began once a participant was entered into 
the study protocol. The sample for this study was comprised of participants from two different 
protocols. Both protocols were part of an NIMH-funded project entitled, “Developmental 
Processes in Schizophrenic Disorders.” One of the protocols (Sample 3) was for a study called 
“Improving and Predicting Work Outcome in Recent-Onset Schizophrenia” and was an 18-
month study comparing two psychosocial interventions (either Individual Placement and Support 
and Workplace Fundamentals Module or a Brokered Vocational Rehabilitation). The other 
protocol (referred to as Sample 4) was for a study titled “Cognitive Remediation, Medication 
Adherence, and Work Outcome in Recent-Onset Schizophrenia” and was a 12-month study 
comparing long-acting injectable risperidone to oral risperidone. The 12-month period of data 
used for this study did not begin at the randomization baseline, rather it began once a participant 
started attending the Aftercare Program and the assessment of psychiatric symptoms and 
medication adherence commenced. Medication ratings, SANS and BPRS data gathered over the 
course of 12 months were analyzed for the purpose of this study. There was an attrition rate of 
approximately 24% over the course of the one-year study.  
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All adherence and symptom data were compiled into one-month intervals to facilitate 
alignment of the adherence and symptom data for 12 consecutive time periods during the follow 
through period. This approach also allowed for BPRS ratings, typically made every two weeks, 
and adherence ratings, typically made every one- to-two weeks, to be combined into somewhat 
longer one-month periods in order to provide greater stability of the ratings. All BPRS ratings 
periods less than two weeks and exceeding 13 weeks were excluded from analysis. Both long 
adherence and symptom intervals (rating periods that exceeded four weeks) were divided and 
included into the weighted means of multiple monthly means. BPRS ratings that crossed into 
more than one monthly interval were placed into the monthly interval that corresponded to the 
date of the rating.  The same was done for medication adherence ratings.  
Each variable for both medication adherence and symptom ratings were merged to create 
mean values for one-month intervals. Specifically, all of a participant’s ratings for a particular 
variable were added together and a mean value was calculated to establish a single value for each 
variable to represent one month. Mean values for one-month intervals were calculated for each 
symptom variable and medication adherence ratings. However, the values were weighted based 
on the duration of the rating period. For example, if one rating period lasted 14 days, another 7 
days, and another 7 days, the first rating would represent 50% of the monthly rating value, and 
the second and third ratings would both represent 25% of the total monthly rating. Intervals were 
determined based on four-week intervals following each individual’s start date into the study.  
Some medication adherence rating periods covered multiple months of time. The average length 
of medication adherence rating periods was 20.0 days (SD = 16.6). The average time covered by 
the BPRS ratings was 17.9 days (SD = 6.1). To determine whether there were gaps in the period 
of time covered in both medication adherence and symptom ratings, the data set was arranged by 
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anchoring time periods to the end date of a rating period. The number of participants with more 
than 12 months of data was limited, so only the first 12 months of adherence data and symptom 
data were analyzed for each participant.  
Table 1 
 
Sample Characteristics at Study Entry for Recent-Onset Schizophrenia Patients 
 
  Sample 3 (n = 65)  Sample 4 (n = 83) Combined (n = 148) 
Mean Age (SD) 23.6 (4.0) 21.6 (3.7) 22.5 (4.0) 
Mean Education 
(SD) 13.3 (1.9) 12.5 (1.8) 12.8 (1.9) 
Mean number of 
months since 
psychosis onset 
(SD) 
  
8.3 (9.8) 
  
7.8 (6.6) 
  
8.0 (8.2) 
Gender 69% Male 76% Male 73% Male 
Marital Status Single                      94% 
Married                     3% 
Separated                  3% 
Single                      95% 
Married                     5% 
Separated                  0% 
Single                      95% 
Married                     4% 
Separated                  1% 
Race Caucasian                49%  
Asian                       12% 
Pacific Islander         3% 
Native American       0% 
African-American   21% 
Mixed                      15% 
Caucasian                48%  
Asian                       11% 
Pacific Islander         1% 
Native American       5% 
African-American   28% 
Mixed                        7% 
Caucasian                 48%  
Asian                        11% 
Pacific Islander          2% 
Native American        3% 
African-American    25% 
Mixed                       11% 
Ethnicity 43% Hispanic 42% Hispanic 42% Hispanic 
Diagnosis Schizophrenia       64% 
Schizoaffective     15% 
Schizophreniform 21% 
Schizophrenia          55% 
Schizoaffective        14% 
Schizophreniform    31% 
Schizophrenia          59% 
Schizoaffective        14% 
Schizophreniform    27% 
 
Descriptive Analysis 
 Descriptive analysis of the symptom ratings revealed that there was very little variance in 
the symptom levels. Table 2 provides descriptive summaries of the symptom ratings aggregated 
across all subjects and across all 12 rating periods. Thus, the relatively small standard deviations 
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represent both reduced variance between-subjects as well as within-subjects over the 12-month 
period of this study. BPRS Self-Neglect had the least amount of variance in ratings (SD = 0.70), 
while the most variance in symptom levels occurred with SANS Avolition-Apathy (SD = 1.58). 
Additionally, symptom levels were generally mild with negative symptom means ranging from 
1.00 for SANS Alogia (as mentioned previously, on a scale of 0 – 5) to 2.35 for SANS 
Avolition-Apathy (also on a scale of 0 – 5). Additionally, as mentioned previously, the BPRS is 
rated on a scale of 1 (not present) to 7 (Extremely Severe). 
Table 2 
 
Descriptive Analysis of Negative Symptom Levels 
 
Negative Symptom N Minimum Maximum Mean Standard 
Deviation 
SANS Affective Flattening 1722 0.00 5.00 1.39 1.28 
SANS Alogia 1722 0.00 5.00 1.00 1.18 
SANS Avolition-Apathy 1722 0.00 5.00 2.35 1.58 
SANS Anhedonia 1722 0.00 5.00 1.85 1.39 
SANS Attention 1721 0.00 5.00 1.07 1.33 
BPRS Motor Retardation 1725 1.00 6.00 1.74 0.97 
BPRS Blunted Affect 1726 1.00 6.00 2.28 1.25 
BPRS Self-Neglect 1725 1.00 7.00 1.36 0.70 
BPRS Emotional Withdrawal 1725 1.00 6.00 1.63 0.98 
 
Bivariate Correlations  
Analysis consisted of bivariate correlations to determine whether there was a significant 
relationship between negative symptoms and medication adherence. When analyzing 12-month 
averages of negative symptom and medication adherence ratings, analyses indicated that the 
presence of negative symptoms was significantly associated with medication nonadherence, 
suggesting that the more nonadherent an individual was with medication, the greater the presence 
of negative symptoms (see Table 3). Correlation coefficients ranged from .08 to .17, with the 
strongest association present between medication nonadherence and the BPRS Emotional 
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Withdrawal, and the weakest association present with the SANS Affective Flattening. When 
examining all SANS global items and BPRS negative symptom items, the only symptoms that 
were not significantly associated with medication nonadherence were SANS Attention (r = .04) 
and BPRS Motor Retardation (r = .01). Although included in the SANS, it should be noted that 
the Attention variable is often considered a cognitive symptom, as opposed to a negative 
symptom.  
Table 3 
 
Pearson Correlations of Mean Values of Negative Symptoms and Mean Medication 
Nonadherence Levels 
 
Negative Symptom Ratings N r p 
SANS Affective Flattening 1223 .08 .007 
SANS Alogia 1223 .12 .000 
SANS Avolition-Apathy  1223 .15 .000 
SANS Anhedonia- Asociality 1223 .10 .001 
SANS Attention 1222 .04 .193 
BPRS Self-Neglect 1226 .13 .000 
BPRS Blunted Affect 1227 .08 .004 
BPRS Emotional Withdrawal 1226 .17 .000 
BPRS Motor Retardation 1227 .01 .817 
 
Bivariate correlations were completed between negative symptoms and medication 
adherence at each time point (one-month intervals) across the course of 12 months to examine 
the possible temporal relationships of the negative symptoms and medication adherence. 
Specifically, negative symptoms were examined in relation to each data point for medication 
adherence (e.g., each monthly mean of ratings for negative symptoms were correlated with each 
monthly mean of ratings for medication adherence). Such analysis was to determine whether the 
presence of negative symptoms was more strongly associated with later medication 
nonadherence, or reversely, if medication nonadherence was more strongly associated with later 
negative symptoms. Generally, initial medication adherence was more strongly associated with 
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levels of negative symptoms in later months than concurrently rated levels of negative symptoms 
for both the SANS (see Table 4) and the BPRS (see Table 5).  
Initial nonadherence predicting later negative symptoms. When examining SANS 
global items in relation to examining medication adherence over time, affective flattening, 
alogia, avolition-apathy, and anhedonia-asociality, all significantly were associated with 
predicting earlier medication nonadherence. In fact, the greater the lag time (e.g., the greater the 
time between the observations) the stronger the relationship between negative symptoms and 
prior medication adherence. Alogia and Avolition-Apathy most strongly predicted medication 
adherence 12 months prior (Alogia, r = .23; Avolition-Apathy, r = .24). Of the negative 
symptoms that significantly predicted previous medication nonadherence, Anhedonia-Asociality 
had the weakest association (1 – 12 months, r = .10 - .19).  
Table 4 
 
Correlations of SANS Negative Symptoms with Previous Ratings of Medication Adherence 
 
Adherence in the 
months prior to 
symptom ratings 
Scale for the Assessment of Negative Symptoms (SANS) Symptom Ratings 
Affective 
Flattening 
Alogia Avolition-
Apathy 
Anhedonia-
Asociality 
Attention  
12 months prior 
N = 202  
r = .20 
p = .004 
r = .23 
p = .001 
r = .24 
p = .001 
r = .19 
p = .008 
r = .09 
p = .186 
11 months prior  
N = 289 
r = .16 
p = .007 
r = .24 
p = .000 
r = .21 
p = .000 
r = .15 
p = .010 
r = .10 
p = .088 
10 months prior  
N = 375 
r = .16 
p = .001 
r = .26 
p = .000 
r = .22 
p = .000 
r = .16 
p = .002 
r = .06 
p = .224 
9 months prior  
N = 460 
r = .14 
p = .004 
r = .24 
p = .000 
r = .21 
p = .000 
r = .12 
p = .014 
r = .06 
p = .239 
8 months prior 
N = 550 
r =.15 
p = .000 
r = .24 
p = .000 
r = .19 
p = .000 
r = .12 
p = .003 
r = .04 
p = .382 
7 months prior 
N = 639 
r = .13 
p = .001 
r = .21 
p = .000 
r = .17 
p = .000 
r = .13 
p = .001 
r = .02 
p = .542 
6 months prior 
N = 727 
r = .11 
p = .002 
r = .20 
p = .000 
r = .16 
p = .000 
r = .12 
p = .001 
r  = .03 
p = .426 
5 months prior 
N = 818 
r  = .11 
p = .002 
r = .18 
p = .000 
r = .13 
p = .000 
r = .10 
p = .003 
r = .03 
p = .356 
(continued) 
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Adherence in the 
months prior to 
symptom ratings 
Scale for the Assessment of Negative Symptoms (SANS) Symptom Ratings 
Affective 
Flattening 
Alogia Avolition-
Apathy 
Anhedonia-
Asociality 
Attention  
4 months prior 
N = 908 
r =  .10 
p = .002 
r = .19 
p = .000 
r = .13 
p = .000 
r = .11 
p = .001 
r = .02 
p = .603 
3 months prior 
N = 999 
r = .08 
p = .010 
r = .18 
p = .000 
r = .14 
p = .000 
r = .11 
p = .001 
r = .04 
p = .210 
2 months prior 
N = 1097 
r = .09 
p = .003 
r = .17 
p = .000 
r = .16 
p = .000 
r = .11 
p = .000 
r = .04 
p = .158 
1 months prior 
N = 1190 
r = .09 
p = .001 
r = .15 
p = .000 
r = .18 
p = .000 
r = .10 
p = .001 
r = .03 
p = .280 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
 
The general trend of initial medication nonadherence being strongly associated with later 
negative symptoms was also found when analyzing BPRS data. Specifically, the association 
between medication nonadherence and negative symptoms became stronger the greater the 
temporal distance. The strongest temporal relationship with medication nonadherence was the 
BPRS item Blunted Affect (1 – 12 months, r = .07 - .21). The weakest association was 
medication nonadherence and Self-Neglect, and it varied in significance over time. Specifically, 
the data suggests that initial medication nonadherence predicted BPRS Self-Neglect one, two, 
three, four, seven, and eight months later. There does not appear to be a clear explanation for this 
inconsistency in association. Overall, the strength of association between BPRS negative 
symptom variables and prior medication adherence ranged from r = .07 to r = .21.  
Table 5 
 
Correlations of BPRS Negative Symptoms with Previous Ratings of Medication Adherence 
  
Adherence in the 
months prior to 
symptom ratings 
Brief Psychiatric Rating Scale (BPRS) Symptom Ratings  
Self-Neglect Blunted Affect Emotional 
Withdrawal 
Motor 
Retardation 
12 months prior  
N = 203 
r = .11 
p = .116 
r = .21 
p = .002 
r = .15 
p = .030 
r = .13 
p = .069 
11 months prior  
N = 290 
r = .02 
p = .684 
r =  .19 
p = .002 
r = .11 
p = .056 
r = .08 
p = .199 
(continued) 
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Adherence in the 
months prior to 
symptom ratings 
Brief Psychiatric Rating Scale (BPRS) Symptom Ratings 
Self-Neglect Blunted Affect Emotional 
Withdrawal 
Motor 
Retardation 
10 months prior  
N = 376 
r = .08 
p = .134 
r = .21 
p = .000 
r = .14 
p = .007 
r = .10 
p = .049 
9 months prior  
N = 462 
r = .08 
p = .076 
r = .13 
p = .005 
r = .16 
p = .000 
r = .05 
p = .330 
8 months prior 
N = 552 
r = .08 
p = .049 
r = .15 
p = .000 
r = .16 
p = .001 
r = .05 
p = .256 
7 months prior 
N = 641 
r = .11 
p = .006 
r = .14 
p = .000 
r = .18 
p = .000 
r = .04 
p = .364 
6 months prior 
N = 729 
r = .05 
p = .179 
r = .11 
p = .002 
r = .16 
p = .000 
r = .02 
p = .510 
5 months prior 
N = 820 
r = .04 
p = .315 
r = .10 
p = .004 
r = .16 
p = .000 
r = -.00 
p = .973 
4 months prior 
N = 911 
r = .08 
p = .021 
r = .09 
p = .007 
r = .17 
p = .000 
r = -.00 
p = .906 
3 months prior 
N = 1002 
r = .11 
p = .000 
r = .07 
p = .022 
r = .18 
p = .000 
r = .01 
p = .692 
2 months prior 
N = 1100 
r = .12 
p = .000 
r = .08 
p = .010 
r = .18 
p = .000 
r = .01 
p = .759 
1 months prior 
N = 1194 
r = .11 
p = .000 
r = .09 
p = .001 
r = .17 
p = .000 
r = .01 
p = .642 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
 
Initial negative symptoms predicting later medication nonadherence. Bivariate 
correlation data analysis also explored whether there was a general trend of association with the 
presence of negative symptoms predicting medication nonadherence at a later time. Overall, this 
data analysis indicated there was not a robust association between the presence of negative 
symptoms and medication nonadherence. Although SANS Apathy was suggested to precede 
medication nonadherence one, two, three, and four months later, the relationship was no longer 
significant when looking at temporal lags longer than four months. None of the other SANS 
variables were significantly related to medication adherence at a later date in time (see Table 6). 
BPRS Self-Neglect and BPRS Emotional Withdrawal were significant in each of the first four 
months and six months (respectively) preceding medication nonadherence (see Table 7). There 
was no directional relationship between medication nonadherence and BPRS Blunted Affect 
	   49 
over the course of one year. Although SANS Apathy was suggested to precede medication 
nonadherence one, two, three, and four months later, the relationship was no longer significant 
when looking at temporal lags longer than four months. None of the other SANS variables were 
significantly related to medication adherence at a later date in time (see Table 6). 
Table 6 
 
Correlations of SANS Negative Symptoms with Subsequent Ratings of Medication Adherence 
   
Adherence in 
the months after 
symptom ratings 
Scale for the Assessment of Negative Symptoms (SANS) Symptom Ratings 
Affective 
Flattening 
Alogia Avolition-
Apathy 
Anhedonia-
Asociality 
Attention  
12 months later 
N = 71 
r = .07 
p = .561 
r = -.05 
p = .662 
r = .15 
p = .199 
r = -.09 
p = .461 
r = -.02 
p = .862 
11 months later 
N = 153 
r = -.05 
p = .568 
r = -.09 
p = .291 
r = .08 
p = .301 
r = -.01 
p = .880 
r = -.03 
p = .705 
10 months later 
N = 237 
r = -.04 
p = .514 
r = -.07 
p = .317 
r = .11 
p = .106 
r =  -.01 
p = .838 
r = -.06 
p = .375 
9 months later 
N = 321 
r = -.09 
p = .120 
r = -.09 
p = .130 
r = .11 
p = .048 
r = .02 
p = .748 
r = -.08 
p = .167 
8 months later 
N = 407 
r = -.09 
p = .065 
r = -.10 
p = .036 
r = .09 
p = .062 
r = -.00 
p = .991 
r = -.06 
p = .209 
7 months later 
N = 494 
r = -.08 
p = .062 
r = -.08 
p = .077 
r = .07 
p = .108 
r = -.02 
p = .721 
r = -.08 
p = .068 
6 months later 
N = 586 
r = -.07 
p = .095 
r = -.05 
p = .237 
r = .06 
p = .126 
r = -.02 
p = .633 
r = -.07 
p = .118 
5 months later 
N = 685 
r = -.08 
p = .048 
r = -.03 
p = .439 
r = .07 
p = .066 
r =  .02 
p = .566 
r = -.03 
p = .382 
4 months later 
N = 782 
r = -.07 
p = .053 
r = -.02 
p = .602 
r = .09 
p = .012 
r = .07 
p = .068 
r = -.03 
p = .357 
3 months later  
N = 881 
r = -.02 
p = .635 
r = .02 
p = .563 
r = .10 
p = .004 
r = .06 
p = .096 
r = -.02 
p = .548 
2 months later  
N = 987 
r = .02 
p = .570 
r = .05 
p = .156 
r = .09 
p = .005 
r = .06 
p = .053 
r = .01 
p = .845 
1 month later  
N = 1102 
r = .05 
p = .094 
r = .09 
p = .002 
r = .12 
p = .000 
r = .08 
p = .009 
r = .04 
p = .227 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
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Table 7 
 
Correlations of BPRS Negative Symptoms with Subsequent Ratings of Medication Adherence   	  
Adherence in the 
months after 
symptom ratings 
Brief Psychiatric Rating Scale (BPRS) Symptom Ratings  
Self-Neglect Blunted Affect Emotional 
Withdrawal 
Motor 
Retardation 
12 months later 
N = 71 
r = -.02 
p = .847 
r = .02 
p = .866 
r = -.01 
p = .916 
r = -.02 
p = .899 
11 months later 
N = 154 
r = -.00 
p = .975 
r = -.04 
p = .667 
r = .01 
p = .916 
r = -.04 
p = .624 
10 months later 
N = 238 
r = .00 
p = .961 
r = -.07 
p = .263 
r = .06 
p = .328 
r = -.05 
p = .471 
9 months later 
N = 322 
r = -.00 
p = .955 
r = -.08 
p = .159 
r = .03 
p = .575 
r = -.04 
p = .453 
8 months later 
N = 408 
r = -.03 
p = .510 
r = -.09 
p = .065 
r = .03 
p = .537 
r = -.07 
p = .169 
7 months later 
N = 496 
r =  -.02 
p = .613 
r = -.08 
p = .069 
r = .08 
p = .079 
r = -.09 
p = .050 
6 months later 
N = 588 
r = .03 
p = .466 
r = -.06 
p = .166 
r = .12 
p = .004 
r = -.07 
p = .076 
5 months later 
N = 687 
r = .04 
p = .283 
r = -.07 
p = .073 
r = .12 
p = .002 
r = -.08 
p = .036 
4 months later 
N = 784 
r = .12 
p = .001 
r = -.07 
p = .042 
r = .12 
p = .001 
r = -.07 
p = .050 
3 months later  
N = 884 
r = .09 
p = .005 
r = -.03 
p = .437 
r = .13 
p = .000 
r = -.03 
p = .338 
2 months later  
N = 990 
r = .07 
p = .021 
r = .02 
p = .633 
r = .13 
p = .000 
r = -.02 
p = .547 
1 month later  
N = 1105 
r = .11 
p = .000 
r = .05 
p = .108 
r = .17 
p = .000 
r = -.01 
p = .772 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
 
Generalized Linear Mixed Model (GLMM) 
 GLMM was completed as a mixed model to analyze the amount of correspondence 
between adherence and negative symptoms, while controlling for repeated observations within-
subjects (see Table 8). Therefore differences between related means of negative symptoms over 
the course of 12 months (and therefore 12 data points) in relation to medication adherence were 
analyzed. The negative symptoms that were significantly associated with medication adherence 
(as the independent variable) were the BPRS Negative Symptom Factor, F(1,1214) = 5.1, p = 
	   51 
.024; BPRS Blunted Affect F(1,1205) = 4.6, p = .032; BPRS Emotional Withdrawal F(1, 1223) = 
8.9, p = .003; BPRS Self-Neglect F(1, 1222) = 14.7, p = .000; SANS Alogia F(1, 1218) = 4.4, p 
= .035; SANS Affective Flattening F(1, 1201) = 4.1, p = .044; and SANS Attention F(1, 1217) = 
4.5, p = .035.   
However, BPRS Motor Retardation, F(1, 1224) = 0.0, p = .847; SANS Avolition-Apathy, 
F(1, 1214) = 1.0, p = .313; and SANS Anhedonia-Asociality, F(1, 1202) = 1.4, p = .231; over the 
12 time intervals were not associated with levels of medication adherence over the 12 rating 
periods.  
Table 8 
 
GLMM with Medication Adherence as the Independent Variable 
 
Symptom Variable Estimate Standard 
Error of 
Estimate 
df 
(Numerator, 
Denominator) 
F Significance 
(p)  
BPRS 
Negative Symptom 
Factor* 
.051 .023 (1, 1214) 5.1 .024 
Blunted Affect .066 .031 (1,1205) 4.6 .032 
Emotional Withdrawal .085 .029 (1,1223) 8.9 .003 
Motor Retardation .005 .027 (1,1224) 0.0 .847 
Self-Neglect .080 .021 (1,1222) 14.7 .000 
SANS 
Affective Flattening .063 .031 (1,1201) 4.1 .044 
Alogia .064 .031 (1,1218) 4.4 .035 
Avolition-Apathy .039 .039 (1,1214) 1.0 .313 
Anhedonia .038 .032 (1,1202) 1.4 .231 
Attention .074 .035 (1,1217) 4.5 .035 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
*Mean of BPRS Withdrawal and Motor Retardation variables  
 
Initial nonadherence predicting later negative symptoms. Similar to the bivariate 
correlations, repeated measures Analysis of Variance was conducted in a mixed model (GLMM) 
approach in order to examine the temporal relationship between medication adherence and 
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negative symptoms. Specifically, analyses were conducted to examine whether there was a 
significant association with medication adherence in the months preceding negative symptoms 
(see Table 9; see Appendices E - X).  
Table 9 
 
GLMM of Initial Medication Nonadherence Predicting Later Negative Symptoms 
 
 Medication adherence months prior (F values) 
Symptom 12 11 10 9 8 7 6 5 4 3 2 1 
SANS  
Affective Flattening 6.7        4.7  3.4 5.6 
Alogia 7.3 5.1       6.9 5.3 12.0 11.0 
Avolition-Apathy 11.8  6.7 6.8        5.9 
Anhedonia-
Asociality 
9.1          3.9 6.2 
Attention          4.2 8.2 5.0 
BPRS 
Negative Symptom 
Factor 
12.1           4.5 
Self-Neglect 6.7   5.1      10.4 11.7  
Blunted Affect 5.7  4.6         4.4 
Emotional 
Withdrawal 
5.4     6.1     5.7 6.3 
Motor Retardation 8.9            
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
 
The data suggests that initial medication nonadherence was significantly associated with 
SANS Affective Flattening ratings one month, F(1,1168) = 5.6, p = .018; two months, F(1,1073) 
= 3.4, p = .068; four months, F(1,878) = 4.7, p = .031; and twelve months, F(1,159) = 6.7, p = 
.011 later (see Appendix E). There was a similar pattern when examining the relationship 
between initial medication nonadherence preceding later SANS Alogia ratings in that there was a 
significant association when medication nonadherence preceded negative symptoms by only a 
few months and then again with much longer gaps in time (see Appendix F). For example, SANS 
Alogia was significantly associated with medication adherence one month, F(1,1183) = 11.0, p = 
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.001; two months, F(1,1086) = 12.0, p = .001; three months, F(1,985) = 5.3, p = .022; and four 
months prior, F(1,893) = 6.9, p = .009. Then medication adherence was significantly associated 
with SANS Alogia again when medication adherence preceded it by eleven months, F(1,253) = 
5.1, p = .024; and twelve months, F(1,141) = 7.3, p = .008. SANS Avolition-Apathy was 
significantly associated with medication nonadherence one month, F(1,1178) = 5.9, p = .015; 
nine months, F(1,427) = 6.8, p = .010; ten months, F(1,341) = 6.7, p = .010; and twelve months, 
F(1,157) = 11.8, p = .001 prior (see Appendix G). In similar fashion, medication nonadherence 
was significantly associated with SANS Anhedonia-Asociality one, F(1,1162) = 6.2, p = .013 
and two, F(1,1067) = 3.9, p = .047 months later, and then again twelve months later, F(1,180) = 
9.1, p = .003 (see Appendix H). Lastly, initial medication nonadherence was significantly 
associated with SANS Attention ratings one, F(1,1181) = 5.0, p = .026; two, F(1,1088) = 8.2, p = 
.004; and three, F(1,990) = 4.2, p = .041 months later (see Appendix I).  
 Regarding the GLMM exploring the temporal relationship between medication adherence 
and BPRS ratings, some symptom variables demonstrated the same pattern observed with the 
SANS, in which initial medication nonadherence preceding negative symptoms was strongly 
associated with shorter lags of time (e.g., one, two, or three months) and then again with very 
long lags of time (e.g., twelve months). For example, medication nonadherence was significantly 
associated with BPRS Negative Symptom Factor one month, F(1,1182) = 4.5, p = .033 and 
twelve months later, F(1,164) = 12.1, p = .001 (see Appendix J). BPRS Self-Neglect was 
significantly associated with medication nonadherence in the preceding two, F(1,1097) = 11.7, p 
= .001; three, F(1,998) = 10.4, p = .001; nine, F(1,450) = 5.1, p = .025; and twelve, F(1,201) = 
6.7, p = .011 months (see Appendix K). Medication nonadherence was significantly associated 
with BPRS Blunted Affect one month, F(1,1172) = 4.4, p = .037; ten months, F(1,356) = 4.6, p = 
	   54 
.033; and twelve months, F(1,152) = 5.7, p = .018 later (see Appendix L). Similar to other 
negative symptoms, BPRS Emotional Withdrawal was significantly associated with preceding 
initial medication nonadherence with a short time lag then also a long lag of time. Specifically, 
medication nonadherence was significantly associated with BPRS Emotional Withdrawal one 
month, F(1,1191) = 6.3, p = .013; two months, F(1,1097) = 5.7, p = .017; and twelve months, 
F(1,199) = 5.4, p = .021 later (see Appendix M). However, BPRS Emotional Withdrawal was 
also significantly associated with medication nonadherence seven months prior, F(1,635) = 6.1, p 
= .014. Notably, BPRS Motor Retardation was only significantly associated with prior 
medication nonadherence when it was twelve months prior, F(1,182) = 8.9, p = .003 (see 
Appendix N).  
Initial negative symptoms predicting later medication nonadherence. Generalized 
linear mixed models were also conducted to examine the temporal relationship between negative 
symptoms and subsequent medication nonadherence (see Table 10). SANS Affective Flattening 
(see Appendix O) was only significantly associated with subsequent medication nonadherence 
when preceding medication nonadherence by four, F(1,779) = 5.9, p = .015; and five months 
F(1,681) = 6.0, p = .015. SANS Attention and SANS Alogia were only significantly associated 
with later medication nonadherence when preceding nonadherence by one month, F(1,1092) = 
4.5, p = .034; and eight months, F(1,404) = 7.6, p = .006; respectively (see Appendices P and Q). 
There were no significant associations between negative symptoms and medication adherence 
when examining medication adherence in the months following SANS Avolition-Apathy (see 
Appendix R) and SANS Anhedonia-Asociality (see Appendix S).  
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Table 10 
 
GLMM of Initial Negative Symptoms Predicting Later Medication Nonadherence 	  
 Medication adherence months later (F values) 
Symptom 1 2 3 4 5 6 7 8 9 10 11 12 
SANS  
Affective Flattening    5.9 6.0        
Alogia         7.6    
Avolition-Apathy             
Anhedonia-
Asociality 
            
Attention 4.5            
BPRS 
Negative Symptom 
Factor 
            
Self-Neglect    13.8   8.0      
Blunted Affect    9.0 5.9        
Emotional 
Withdrawal 
9.2     4.1       
Motor Retardation    3.9 7.1        
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
 
 The BPRS Negative Symptom Factor was the only BPRS symptom variable that was not 
significantly associated with later medication nonadherence at any time interval (see Appendix 
T). Additionally, although there were significant associations at one or two time points, there 
was no notable pattern of significant associations of BPRS negative symptoms preceding later 
medication nonadherence. BPRS Self-Neglect was significantly associated with medication 
nonadherence four months, F(1,770) = 13.8, p = .000; and seven months, F(1,476) = 8.0, p = 
.005 later (see Appendix U). Medication nonadherence was significantly associated with BPRS 
Blunted Affect four months, F(1,781) = 9.0, p = .003; and five months, F(1,684) = 5.9, p = .016 
earlier (see Appendix V).  There were also significant associations with BPRS Emotional 
Withdrawal and medication nonadherence one month later, F(1,1073) = 9.2, p = .003; and also 
six months later, F(1,528) = 4.1, p = .042 (see Appendix W). BPRS Motor Retardation was only 
significantly associated with later medication nonadherence when it preceded medication 
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nonadherence by four months, F(1,769) = 3.9, p = .050; and five months, F(1,675) = 7.1, p = 
.008 (see Appendix X). 
GLMM with Test of Mediation 
A GLMM was conducted in order to examine the relationships between medication 
adherence and negative symptoms while controlling for reality distortion (see Table 11). Reality 
distortion was controlled because it was suspected to be a third variable that may mediate the 
significant relationship between negative symptoms and medication adherence.  The Reality 
Distortion variable was comprised of the means of the BPRS variables Hallucinations and 
Unusual Thought Content. By controlling the variation caused by Reality Distortion, it increased 
the likelihood of observing the actual relationship between medication adherence and negative 
symptoms. The negative symptoms that were significantly associated with medication adherence 
(as the independent variable) were the BPRS Negative Symptom Factor, F(1,1214) = 5.1, p = 
.024; BPRS Blunted Affect, F(1,1205) = 4.6, p = .032; BPRS Emotional Withdrawal, F(1,1223) 
= 8.9, p = .003; SANS Affective Flattening, F(1,1201) = 4.1, p = .044; and SANS Alogia, 
F(1,1218) = 4.4, p = .035. BPRS Motor Retardation, SANS Avolition-Apathy, and SANS 
Anhedonia over the 12 time intervals were not associated with levels of medication adherence 
over the 12 rating periods. However, when the BPRS Reality Distortion was controlled for as a 
covariate, the amount of correspondence between adherence and negative symptoms 
significantly lessened. When controlling for Reality Distortion, the only variables in which the 
significant associations with medication adherence remained were the BPRS Negative Symptom 
Factor, F(1,1213) = 4.1, p = .024; BPRS Emotional Withdrawal, F(1,1223) = 7.6, p = .006; and 
BPRS Self-Neglect, F(1,1222) = 10.6, p = .001. BPRS Blunted Affect, SANS Affective 
Flattening, SANS Alogia and SANS Attention were no longer significantly associated with 
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medication adherence when Reality Distortion was controlled. Overall, once Reality Distortion 
was controlled for as a mediating variable, the significant association between negative 
symptoms and medication adherence weakened, indicating that Reality Distortion is in fact a 
variable mediating the relationship between the two variables.  
Table 11 
 
GLMM with Medication Adherence as the Independent Variable Controlling for Reality 
Distortion 
 
Dependent 
Variable 
 Estimate Standard Error 
of Estimate 
df (Numerator, 
Denominator) 
F Significance 
(p)  
BPRS 
Negative Symptom 
Factor* 
c** .051 .023 (1,1214) 5.1 .024 
c’*** .046 .023 (1,1213) 4.1 .042 
Blunted Affect c .066 .031 (1,1205) 4.6 .032 
  c’ .059 .031 (1,1204) 3.7 .053 
Emotional 
Withdrawal 
c .085 .029 (1,1223) 8.9 .003 
c’ .079 .029 (1,1223) 7.6 .006 
Motor Retardation c .005 .027 (1,1224) 0.0 .847 
c’ .002 .027 (1,1222) 0.0 .953 
Self-Neglect c .080 .021 (1,1222) 14.7 .000 
c’ .067 .021 (1,1222) 10.6 .001 
SANS 
Affective 
Flattening 
c .063 .031 (1,1201) 4.1 .044 
c’ .051 .031 (1,1202) 2.7 .098 
Alogia c .064 .031 (1,1218) 4.4 .035 
c’ .059 .031 (1,1217) 3.7 .056 
Avolition-Apathy c .039 .039 (1,1214) 1.0 .313 
c’ .024 .039 (1,1218) 0.4 .534 
Anhedonia c .038 .032 (1,1202) 1.4 .231 
c’ .026 .031 (1,1206) 0.7 .409 
Attention c .074 .035 (1,1217) 4.5 .035 
c’ .064 .035 (1,1216) 3.3 .069 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
* Mean of BPRS Withdrawal and Motor Retardation variables 
** Without covariate 
*** Controlling for covariate of Reality Distortion 
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Chapter 4: Discussion 
This chapter presents a summary of this study, including a summary of the results 
presented in Chapter 3. A discussion of the implications of this study, this study’s limitations, 
and potential directions for future research will be provided.    
This study explored the relationship between the negative symptoms and medication 
nonadherence in individuals who (at the onset of the study) were within two years of their first 
psychotic episode. It is important to learn more about this relationship because research suggests 
that the severity of negative symptoms is a main factor impacting the outcome of treatment for 
schizophrenia (Brier & Berg, 1999; Ventura et al., 2009). The presence of negative symptoms in 
schizophrenia is associated with poor prognosis and functional outcome because they impair 
motivation and interests (Makinen et al., 2008; Ventura et al., 2009; Woo & Keatinge, 2008). 
Further, negative symptoms tend to be stable and enduring throughout the course of the illness in 
part because they are resistant to medication and psychosocial interventions (Hanson et al., 2010; 
Rollins et al, 2010). The evidence for whether negative symptoms are responsive to medication 
adherence is mixed, and this author is only aware of five studies prior to this study that have 
explored a potential relationship between negative symptoms and medication nonadherence 
(Erhart et al., 2006). 
The sample for this study was comprised of individuals who upon study entry were in the 
midst of their first psychotic episode. Over the course of 12 months, symptom ratings were 
established from SANS and BPRS ratings and medication adherences ratings were created based 
on pill counts, plasma concentrations of risperidone and 9-hydroxyrisperidone, self-report of 
nonadherence to a treatment team member, clinician assessment and Medication Event 
Monitoring System (for Sample 4, only). Ratings were consolidated into one-month means for 
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data analysis and analysis consisted of bivariate correlations to examine the relationship between 
negative symptoms and medication adherence. Data analysis also consisted of generalized linear 
mixed models.  
In the sample used for this study, bivariate correlations revealed a significant relationship 
between higher levels of negative symptoms and higher levels of medication nonadherence. 
Specifically, greater nonadherence to the second-generation oral antipsychotic medication 
risperidone was associated with higher levels of affective flattening (and blunted affect), alogia, 
avolition-apathy, anhedonia-asociality, self-neglect, and emotional withdrawal, in bivariate 
correlations. Of the negative symptoms examined, the BPRS variable Emotional Withdrawal had 
the strongest association with medication nonadherence and SANS Affective Flattening had the 
weakest association. BPRS Motor Retardation and SANS Attention were the only variables not 
significantly correlated with medication nonadherence. It is possible that the lack of significance 
between medication nonadherence and SANS Attention may relate to the common view that this 
variable is more of a cognitive symptom than a negative symptom.  
The results of bivariate correlations also indicate that there appears to be a temporal 
relationship between negative symptoms and medication nonadherence. Specifically, medication 
nonadherence predicted the presence of negative symptoms at a later time. There was not a 
significant pattern of association when exploring the temporal relationship of negative symptoms 
preceding medication nonadherence. Interestingly, bivariate correlations revealed that the more 
time that passed after medication nonadherence, the stronger the relationship between negative 
symptoms and earlier medication nonadherence. Medication nonadherence most strongly 
preceded later increases in SANS Alogia, SANS Avolition-Apathy, and BPRS Affective 
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Flattening. The weakest association between medication nonadherence and later negative 
symptom levels was between SANS Anhedonia-Asociality and BPRS Self-Neglect.  
GLMM analysis examined the relationship between medication adherence and negative 
symptoms while controlling for repeated observations within subjects. Similar to the bivariate 
correlations, the mixed model analyses revealed that overall there was a significant relationship 
between negative symptoms and medication nonadherence. Also similar to the bivariate 
correlations, GLMM analysis was completed to explore the temporal relationship of negative 
symptoms and medication adherence with time lags. However, unlike the bivariate correlations 
examining time lags, much of the significant association disappeared when time lags were 
explored with GLMM, which controlled for the repeated observations within subjects. There 
may have been a few subjects for whom the temporal lag pattern was most apparent, and 
consequently, it is possible that once repeated observations within subjects was controlled much 
of the significant association disappeared. 
Although much of the temporal relationship with medication nonadherence preceding 
negative symptoms dissipated once repeated observations within subjects was controlled, there 
was still an observable temporal pattern in which initial medication nonadherence was 
significantly associated with an increase in negative symptoms in short intervals of time (e.g., 
approximately one – three months later) and then again with much longer lags of time (e.g., 
eleven or twelve months later). This pattern of temporal relationships was evident with SANS 
Affective Flattening, SANS Alogia, SANS Avolition-Apathy, SANS Anhedonia-Asociality, 
BPRS Negative Symptom Factor, BPRS Self-Neglect, and BPRS Blunted Affect. SANS 
Attention, BPRS Emotional Withdrawal, and BPRS Motor Retardation were also significantly 
associated with preceding medication nonadherence, although the pattern of association with 
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shorter and then much longer intervals was not present, it was either one or the other, or both 
short and long time lags in addition to other intervals of significant associations.  
However, there was also very little variation in symptom ratings and medication 
nonadherence ratings over the 12 month rating period. There may have been little variation in 
symptom ratings since negative symptoms are typically stable over the course of the illness and 
are also are minimally responsive to antipsychotic medication (Subotnik, Nuechterlein, Ventura, 
Green, & Hwang, 1998). The level of negative symptoms was also mild in this sample. 
Regarding the low levels of medication nonadherence, it is possible that this is because some of 
the factors related to medication nonadherence previously discussed were controlled or 
decreased in this study. For example, cost of care and ease of access to health care providers 
were controlled by providing free services and also providing transportation to and from the 
UCLA Aftercare Clinic for individuals in this study. The impact of substance use also was 
reduced in this study because of the exclusion criterion for significant substance abuse. It is 
possible that high levels of stability in medication adherence and symptoms over the 12 time 
intervals limited possible relationships between adherence and changes in these symptoms.  
One possible explanation for the temporal relationship of early medication nonadherence 
and later levels in negative symptoms is that there could be a third variable mediating the 
relationship between the two. This is a consideration given that there is little evidence that 
antipsychotic medications improve negative symptoms so it is curious as to why medication 
nonadherence in this study led to an increase in negative symptoms at a later time. Therefore it is 
possible that this significant association does not mean that medication is treating negative 
symptoms per se but rather that the negative symptoms are improving secondary to the 
improvement in positive symptoms. For example, a period of nonadherence to antipsychotic 
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medication might lead to an increase in positive symptoms such as hallucinations or delusions, 
which consequently also leads to higher levels of negative symptoms. This is consistent with the 
findings of Subotnik et al. (2014) indicating that when positive symptoms were controlled for, 
there was no longer a significant relationship between medication adherence and negative 
symptoms.  This is also supported by this study’s GLMM analyses in which the significant 
association between negative symptoms and medication adherence was greatly reduced once the 
impact of reality distortion was controlled. The only symptoms in which the significant 
association remained once reality distortion was controlled were the BPRS Negative Symptom 
Factor, BPRS Emotional Withdrawal, and BPRS Self-Neglect.  
The finding that the strong association between negative symptoms and medication 
nonadherence greatly dissipates once the impact of reality distortion is controlled suggests that 
positive and negative symptoms of psychosis are strongly related, and not independent of one 
another. Further, the relationship between positive and negative symptoms in this study was 
stronger than the relationship between negative symptoms and medication adherence. This 
supports Ventura et al.’s 2003 findings that negative symptom exacerbations occurred 
simultaneously with positive symptom exacerbations to an extent significantly greater than 
chance, suggesting that positive and negative symptom exacerbations are linked to one another. 
It is possible that negative symptoms are a response to positive symptoms, such as 
hallucinations and delusions. For example, a person may socially withdraw (asociality) or 
minimize their speech (alogia) due to paranoia or auditory hallucinations. Or, an individual may 
be preoccupied with internal stimuli (e.g., hearing voices) and consequently no longer have 
interest in activities (anhedonia) or motivation to complete tasks (avolition). If an individual with 
intense auditory hallucinations shuts down by not being willing to make eye contact or converse 
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with others, it likely would be interpreted as negative symptoms. This aligns with recent 
diagnostic changes from the Diagnostic Statistical Manual, 4th Edition, TR to the Diagnostic 
Statistical Manual, 5th Edition. Specifically, subtypes (e.g., Catatonic, Paranoid, etc.) were 
removed from the Schizophrenia diagnosis. The American Psychiatric Association reportedly 
made this change for a few reasons, one of which was to create a dimensional approach to rating 
severity for the core symptoms of schizophrenia in order to capture heterogeneity in symptom 
type, and severity expressed across individuals with psychotic disorders (APA, 2013). This 
change appears to reflect the findings of this dissertation study, that positive and negative 
symptoms are not orthogonal but rather related to one another.  
It is possible that the strong relationship between negative and positive symptoms relates 
to electrodermal activity (EDA). Prior research has demonstrated that heightened autonomic 
responsivity is associated with negative symptoms (Subotnik et al., 2012). Specifically, it 
appears that behaviors similar to negative symptoms (e.g., emotional restriction and social 
withdrawal) may be an attempt to reduce the body’s autonomic over-responsiveness that occurs 
as a response to environmental stress such as expressed emotion (Schell et al., 2005; Subotnik et 
al., 2012). For example, the relationship between negative symptoms and electrodermal activity 
may relate to individuals withdrawing from social interactions and attempting to suppress visible 
reactions and cope with overstimulating environments (Schell et al., 2005). Therefore, high 
expressed emotion predicts both positive and negative symptoms, and both positive and negative 
symptoms are concurrently associated with electrodermal activity. However, if the negative 
symptoms which are associated with increased electrodermal activity are a result of 
environmental stress, they would be secondary rather than primary negative symptoms (Schell et 
al., 2005).  
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Although this dissertation study suggested that positive symptoms are a mediating 
variable in the relationship between medication nonadherence and negative symptoms, even 
when controlling for reality distortion, there was still a significant relationship between the two 
variables. This suggests that positive symptoms only partially mediate the relationship between 
medication adherence and negative symptoms. It is possible that while both positive and negative 
symptoms relate to electrodermal activity, negative symptoms are significantly associated with 
electrodermal activity independent of positive symptoms. Elecrodermal activity and responsivity 
are indicators of sympathetic nervous system (SNS) functioning (Dawson et al., 2010; Subotnik 
et al., 2012). As mentioned, heightened EDA levels, as opposed to reduced EDA levels, are 
present in a subset of schizophrenia patients who have prominent negative symptoms. 
Electrodermal activity has also been shown to be heightened in the weeks preceding a psychotic 
relapse or exacerbation, supporting the idea that electrodermal activity changes in anticipation of 
symptomatic changes (Dawson & Schell, 2002). EDA is a physiological indicator of stress since 
it is controlled by the sympathetic nervous system and consequently, when individuals 
experience psychosocial/environmental stressors, their EDA increases, which then appears to 
contribute to the return of symptoms (Dawson & Schell, 2002; Dawson et al., 2010). One 
possibility for the present study’s findings that medication nonadherence leads to greater 
negative symptoms is that second-generation antipsychotic medication controls electrodermal 
activity. Consequently, once someone is less adherent to psychotropic medication, electrodermal 
activity might increase, leading to a compensatory increase in negative symptoms.  This 
compensatory increase is an attempt to regulate the electrodermal activity and the subsequent 
brewing incipient psychosis by withdrawing from environmental stimulation. Thus, 
antipsychotic medications may allow individuals to tolerate their environment better, thereby 
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lessening the effects of environmental stressors such as high expressed emotion within families. 
This is supported by Subotnik et al’s 2012 finding that the highest levels of negative symptoms 
were observed in individuals who exhibited greater electrodermal activity and also lived in high 
expressed emotion environments. Specifically, negative symptoms were predicted by the 
interaction of high expressed emotion and EDA. Such a finding is also understandable given the 
well-replicated findings that high expressed emotion environments predict psychotic relapse 
(Subotnik et al., 2012). 
As mentioned in Chapter 1, the research exploring a possible relationship between 
negative symptoms and medication nonadherence is mixed and limited. To this author’s 
knowledge, there have only been five studies exploring this relationship prior to this dissertation. 
Additionally, while Subotnik et al. (2014) also explored whether there is a potential temporal 
relationship between medication nonadherence and negative symptoms, it appears that the 
present study is the first to examine this question with fine-grained temporal analyses 
(specifically, one month intervals instead of Subotnik et al.’s [2014] three month intervals). Also 
different from Subotnik et al.’s 2014 study was the method of data analysis and the symptom 
measures used. Subotnik et al. utilized cross-lag panel analyses and the Sobel Test to determine 
causality between medication nonadherence and negative symptoms whereas this study utilized 
GLIMM. This study also utilized the BPRS in addition to the SANS, and was able to compare 
similarities and differences by using both instruments, while Subotnik et al. (2014) measured 
symptoms with the SANS and SAPS. Therefore, by using different data analyses and symptom 
measures, this dissertation study was able to see if Subotnik et al.’s findings could be replicated 
with new measures and with a more detailed analysis of the temporal relationship (as mentioned 
due to the smaller time intervals).  
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Tattan and Creed’s 2001 study exploring this relationship also used the SANS. Consistent 
with the findings of this study, Tattan and Creed found that individuals with lower adherence to 
medication had significantly higher SANS Avolition, Apathy, and Alogia scores. Of interest, 
Tattan and Creed’s findings are consistent with the present study’s findings even though the 
samples were at different stages in the course of their illness. Specifically, this study focused on 
individuals who were early in the course of their psychosis (within two years of their first 
psychotic episode) whereas the duration of illness in Tattan and Creed’s sample ranged from 9 – 
22 years. This suggests that the finding that there is a significant relationship between medication 
adherence and negative symptoms may generalize to the entire course of illness, and not just 
shortly after a first episode of psychosis.  
 Kao and Liu (2010) used the PANSS instead of the SANS or BPRS to assess a 
relationship between symptoms and medication nonadherence, yet they also found a significant 
relationship between the negative symptoms and medication nonadherence. Since they used 
different measures, it is unclear if there were similar findings regarding which negative 
symptoms were more significantly associated with medication nonadherence.  
 Similar to the present study, Steger et al. (2012) explored the relationship between 
negative symptoms and medication adherence using the SANS with the first episode psychosis 
population.  Consistent with the present study, Steger et al. found greater alogia and affective 
flattening in medication nonadherent individuals. They also found that the individuals whose 
negative symptoms resolved at the three-month mark also had lower levels of positive 
symptoms. This may support the idea that there is a significant relationship between positive and 
negative symptoms.  
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A few of the five studies explored the role of insight as a mediator in the relationship 
between negative symptoms and medication nonadherence since there is known relationship 
between poor insight and nonadherence, and insight is negatively correlated with the presence of 
negative symptoms (Chang et al., 2011; Mintz et al., 2003). For example, Baloush-Kleinman et 
al. (2011) identified that the presence of negative symptoms predicted attitudes (including 
insight) towards medication, which in turn predicted adherence. It appears that this dissertation is 
the second study (Subotnik et al., 2014 was the first) to explore the role of positive symptoms 
(e.g., Reality Distortion) as a variable mediating the relationship between negative symptoms 
and medication nonadherence. However, this dissertation appears to be the first study examining 
the presence of a mediator in such a fine-grained temporal analyses, with one-month intervals as 
opposed to three-month intervals.  
Limitations 
This dissertation supports the limited prior research indicating that there is a significant 
relationship between negative symptoms and medication nonadherence. Although there have 
been a few studies which have previously explored this relationship, the current research in this 
area is still very limited and much needed. The results of this study have significant implications 
for treatment and mitigating risk factors for medication nonadherence. However, since the mean 
level of negative symptoms was mild for this study’s sample, it may have limited the ability to 
assess the strength of the relationship between negative symptoms and medication nonadherence. 
It is possible that had higher levels of negative symptoms been present, or if there had been more 
variation in negative symptom levels, the association between negative symptoms and 
medication nonadherence may have been more robust.  
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It is likely that the mild level of negative symptoms is in part attributable to the highly 
controlled and comprehensive level of treatment provided by the UCLA Aftercare Research 
Program. The sample used in this study was controlled in many ways (as mentioned previously 
regarding excluding substance use, etcetera), which is a strength in that it eliminates confounding 
variables in the relationships explored in this study; however, the limitation is that it also impacts 
the ability of these results to be generalized to individuals typically seen in community treatment 
programs. Specifically, common factors contributing to nonadherence (e.g., cost of care and ease 
of access to treatment) were controlled in this study, thus limiting the generalizability of this 
study to community treatment providers. As mentioned above, another limitation related to the 
generalizability of this study is that the sample used for this dissertation had very minimal 
substance use. Because substance abuse is a predictor of medication nonadherence and is also 
commonly comorbid with psychotic disorders, it would be worthwhile for future studies to 
explore the role of negative symptoms in medication non-adherence in this population (Kamali et 
al., 2006; Saddichha, Sur, Sinha, & Khess, 2010).  
Another limitation for this particular study’s exploration of correlates of negative 
symptoms is that it focused on recent first-episode schizophrenia patients. It is unknown whether 
the findings of this study would generalize to individuals at different stages of the course of 
psychosis. Also, the sample included very few individuals with deficit syndrome, which may be 
an ideal subgroup to look at to explore whether there is such a relationship between negative 
symptoms and medication adherence. However, given that severe negative symptoms are often 
debilitating, it may likely be very difficult to recruit and retain individuals with such severe 
negative symptoms in intervention studies.  
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A final limitation of this study relates to the data set construction. Symptom ratings and 
medication adherence ratings that exceeded four weeks were divided and included in multiple 
consecutive monthly means. This limited the chance of finding a temporal trend with the data. 
Specifically, this contributed to there being less within-subject change over time and therefore 
the overall range of ratings was truncated. Consequently, the possibility of identifying the true 
effect size was reduced. 
Future Directions 
The extant literature on this topic is sparse and the present findings require replication. 
Future research should address whether the relationships between negative symptoms and 
medication adherence, and between negative and positive symptoms can be replicated in samples 
of individuals at other stages of the illness (other than first episode), and with other symptom 
measures assessing the presence and level of negative symptoms. Additionally, as mentioned, 
given that there is little evidence that antipsychotic medications address/reduce negative 
symptoms, it is surprising that there was a strong association between earlier medication 
nonadherence and later negative symptoms. The findings of this dissertation suggest that there is 
a significant relationship between positive and negative symptoms, a relationship that appears to 
be more strongly associated than the relationship between negative symptoms and medication 
adherence. Consequently, further research should explore the significant interaction between 
negative and positive symptoms and whether this relationship helps to explain other generally 
understood relationships within psychosis, such as the relationship between negative symptoms 
and poor insight, or the relationship between poor insight and medication nonadherence. It would 
also be beneficial to explore whether there are mediating variables (other than positive 
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symptoms) that contribute to the significant relationship between negative symptoms and 
medication adherence.   
As mentioned, the sample for the current study had well-controlled symptoms, which 
likely contributed to the mild level of negative symptoms, and limited generalizability to 
individuals seen and treated at community treatment centers. Therefore, future research should 
explore whether the relationship between medication nonadherence and negative symptoms 
remains in samples of individuals with a higher level of negative symptoms, and in environments 
that have less control over confounding variables (e.g., access to treatment), so as to see the real-
world applicability of this study’s findings.  
In order to determine whether the significant relationship between medication 
nonadherence and negative symptoms occurs in samples with higher levels of negative 
symptoms, research should be conducted exploring this relationship in individuals with deficit 
syndrome. As a means of learning more about treatment implications of the relationship between 
negative symptoms and medication adherence, future research should explore whether the 
significant temporal relationship between negative symptoms and medication adherence is also 
present in individuals experiencing disorders comorbid with psychosis, such as substance use. 
 It is also unclear why the relationship between negative symptoms and medication 
adherence was stronger the more time that passed between evaluation points. Future research 
should explore potential reasons why this relationship became stronger as more time passed 
between the two points in time. Research should also examine why medication adherence was 
significantly associated with later negative symptoms at smaller intervals of time (e.g., a couple 
months) and then again at longer gaps of time (e.g., 12 months later). Additionally, future 
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research should explore which variables (other than positive symptoms) might serve as mediators 
between negative symptoms and medication nonadherence. 
 The results of this study have the potential to greatly contribute to the clinical treatment 
for first episode schizophrenia since a significant relationship was found between negative 
symptoms and medication adherence. Currently, there are minimal interventions for the 
treatment of negative symptoms, and given the relationships found in this study, further research 
involving negative symptoms as an intervention target should be conducted. 
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Brief	  Psychiatric	  Rating	  Scale	  (Version	  4.0)	  
	  Patient	  Name/ID	  #	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Date	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Rater	  _____________________	  	  Hospital/Location	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Period	  of	  Assessment_____________________________	  	  	  	  	  	  	  	  	  	  	  	  NA	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  4	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  6	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  7	  Not	  Assessed	  	  	  	  	  	  	  Not	  Present	  	  	  	  	  	  	  	  	  Very	  Mild	  	  	  	  	  	  	  	  	  	  	  Mild	  	  	  	  	  	  	  	  	  Moderate	  	  	  	  	  	  	  	  Moderately	  Severe	  	  	  	  	  Severe	  	  	  	  	  	  	  	  Extremely	  Severe	  	  
Rate	  items	  1-­‐14	  on	  the	  basis	  of	  patient’s	  self-­‐report	  during	  interview.	  Note	  items	  7,	  12,	  and	  13	  
are	  also	  rated	  on	  observed	  behavior	  during	  the	  interview.	  	  Mark	  “NA”	  for	  symptoms	  not	  
assessed.	  	  	  	  	  	  	  	  	  	  	   	   	   	   	   	   	   	   	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
PROVIDE	  EXAMPLES:	  
	  1.	   Somatic	  Concern	   	   NA	   1	   2	   3	   4	   5	   6	  	  	  	  	  	  7	  2.	   Anxiety	   	   	   NA	   1	   2	   3	   4	   5	   6	  	  	  	  	  	  7	  3.	   Depression	   	   	   NA	   1	   2	   3	   4	   5	   6	  	  	  	  	  	  7	  4.	   Suicidality	   	   	   NA	   1	   2	   3	   4	   5	   6	  	  	  	  	  	  7	  5.	   Guilt	   	   	   	   NA	   1	   2	   3	   4	   5	   6	  	  	  	  	  	  7	  6.	   Hostility	   	   	   NA	   1	   2	   3	   4	   5	   6	  	  	  	  	  	  7	  7.	   Elevated	  Mood	   	   NA	   1	   2	   3	   4	   5	   6	  	  	  	  	  	  7	  8.	   Grandiosity	   	   	   NA	   1	   2	   3	   4	   5	   6	  	  	  	  	  	  7	  9.	   Suspiciousness	   	   NA	   1	   2	   3	   4	   5	   6	  	  	  	  	  	  7	  10.	   Hallucinations	   	   NA	   1	   2	   3	   4	   5	   6	  	  	  	  	  	  7	  11.	   Unusual	  Thought	  Content	   NA	   1	   2	   3	   4	   5	   6	  	  	  	  	  	  7	  12.	   Bizarre	  Behavior	   	   NA	   1	   2	   3	   4	   5	   6	  	  	  	  	  	  7	  13.	   Self-­‐neglect	   	   	   NA	   1	   2	   3	   4	   5	   6	  	  	  	  	  	  7	  14.	   Disorientation	   	   NA	  	   1	   2	   3	   4	   5	   6	  	  	  	  	  	  7	  	  Rate	  items	  15-­‐24	  on	  the	  basis	  of	  observed	  behavior	  or	  speech	  of	  the	  patient	  during	  the	  interview.	  	  15.	   Conceptual	  Disorganization	   NA	  	   1	   2	   3	   4	   5	   6	   7	  16.	   Blunted	  Affect	   	   NA	  	   1	   2	   3	   4	   5	   6	   7	  17.	   Emotional	  Withdrawal	   NA	  	   1	   2	   3	   4	   5	   6	   7	  18.	   Motor	  Retardation	   	   NA	  	   1	   2	   3	   4	   5	   6	   7	  19.	   Tension	   	   	   NA	  	   1	   2	   3	   4	   5	   6	   7	  20.	   Uncooperativeness	   	   NA	  	   1	   2	   3	   4	   5	   6	   7	  21.	   Excitement	   	   	   NA	  	   1	   2	   3	   4	   5	   6	   7	  22.	   Distractibility	  	   	   NA	  	   1	   2	   3	   4	   5	   6	   7	  23.	   Motor	  Hyperactivity	   	   NA	  	   1	   2	   3	   4	   5	   6	   7	  24.	   Mannerisms	  and	  Posturing	   NA	  	   1	   2	   3	   4	   5	   6	   7	  	  	  Sources	  of	  information	  (check	  all	  applicable):	  	   Explain	  here	  if	  validity	  of	  assessment	  is	  questionable:	  	  	  	  	  	  	  	  	  	  	  	  	  Patient	   	   	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  Symptoms	  possibly	  substance-­‐induced	  	  	  	  	  	  	  	  	  	  	  	  	  Parents/Relatives	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  Under	  reported	  due	  to	  lack	  of	  rapport	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  Mental	  health	  professionals	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  Patient	  uncooperative	  	  	  	  	  	  	  	  	  	  	  	  	  Chart	   	   	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  Difficult	  to	  assess	  due	  to	  formal	  thought	  disorder	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Other	  (e.g.,	  police	  report)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Other	  	  Confidence	  in	  assessment	   	   	   	   	   	   Record	  information:	  	   	   	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  1	  =	  not	  at	  all	  -­‐	  5	  =	  very	  confident	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APPENDIX D 
Scale for the Assessment of Negative Symptoms (SANS) Record Form, Modified by the UCLA 
Center for Research on Treatment and Rehabilitation of Psychosis 
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Scale for the Assessment of Negative Symptoms 
(SANS)* ** 
 
Date:                                                            Patient name/ID: ________________________                                                                 
Rating Period:                                                           	   	  Interviewer:	  	  ____________________________	  	  
O=None 1=Questionable 2=Mild 3=Moderate 4=Marked 5=Severe 	  
AFFECTIVE_FLATTENING_OR_BLUNTING  (Provide Examples) 
 
  1. Unchanging Facial Expression          0  1  2  3  4  5 
         The patient's face appears wooden, changes less than expected  
         as emotional content of discourse changes. 
 
  2.   Decreased Spontaneous Movements                                                                    0  1  2  3  4  5 
          The patient shows few or no spontaneous movements, does  
           not shift position, move extremities, etc. 
 
  3.   Paucity of Expressive Gestures                                                                              0  1  2  3  4  5 
        The patient does not use hand gestures, body position, etc., as  
          an aid to expressing his ideas. 
 
  4.   Poor Eye Contact                                                                                                       0  1  2  3  4  5 
        The patient avoids eye contact or "stares through" interviewer  
         even when speaking. 
 
  5.   Affective Nonresponsivity                                                                                     0  1  2  3  4  5 
      The patient fails to smile or laugh when prompted. 
 
  6.   Lack of Vocal Inflections                                                                                        0  1  2  3  4  5 
        The patient fails to show normal vocal emphasis patterns, is  
         often monotonic. 
 
  7.   Global Rating of Affective Flattening                                                                 0  1  2  3  4  5 
        This rating should focus on overall severity of symptoms,  
         especially  unresponsiveness, eye contact, facial expression, 
         and vocal inflections. 
 
ALOGIA	  
 
8. Poverty of Speech                                                                                                   0  1  2  3  4  5 
        The patient's replies to questions are restricted in the amount, 
          tend to be brief, concrete, and unelaborated. 
 
  9.   Blocking                                                                                                                    0  1  2  3  4  5 
        The patient indicates, either spontaneously or with prompting, 
          that his or her train of thought was interrupted. 
          
10.   Increased Latency of  Response                                                                           0  1  2  3  4  5 
        The patient takes a long time to reply to questions; prompting  
          indicates the patient is aware of the question. 
 
11.   Global Rating of Alogia                                                                                        0  1  2  3  4  5 
         The core feature of alogia is poverty of speech. 
 
AVOLITION-APATHY                                                              (Provide Examples)    
 
12.   Grooming and Hygiene                                                                                        0  1  2  3  4  5 
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         The patient's clothes may be sloppy or soiled, and he or she  
          may have greasy hair, body odor, etc. 
 
13a. Impersistence at Work or School (relative to general population)                               0  1  2  3  4  5 
         Based on the patient’s age and sex, rate the degree to which  
         the patient has difficultyin seeking or maintaining employment, 
         attending school, keeping house, or engaging in volunteer work.    
 
13b. Impersistence at Work or School (relative to selected sample)                         0  1  2  3  4  5       Rate the patient’s impersistence relative to a patient sample  
          chosen by the project principal investigator.  DO NOT include  
          13b in the Global rating of Avolition-Apathy.    
.         
14.   Physical Anergia                                                                                                    0  1  2  3  4  5  
        The patient tends to be physically inert. He or she may sit for  
          hours and does not initiate spontaneous activity. 
 
15.   Global Rating of Avolition-Apathy                                                                   0  1  2  3  4  5 
        Strong weight may be given to one or two prominent symptoms 
          if particularly striking. 
 
ANHEDONIA-ASOCIALITY 
 
16.   Recreational Interests and Activities                                                                 0  1  2  3  4  5 
        The patient may have few or no interests.  Both the quality and 
          quantity of interests should be taken into account. 
 
17.   Sexual Activity                                                                                                       0  1  2  3  4  5 
        The patient may show a decrease in sexual interest and activity, 
          or enjoyment when active. 
 
18.   Ability to Feel Intimacy and Closeness                                                            0  1  2  3  4  5 
        The patient may display an inability to form close or intimate  
          relationships, especially with the opposite sex and family. 
 
19.   Relationships with Friends and Peers                                                               0  1  2  3  4  5 
         The patient may have few or no friends and may prefer to spend 
         all of his or her time isolated. 
 
20.   Global Rating of Anhedonia-Asociality                                                           0  1  2  3  4  5 
         This rating should reflect overall severity, taking into account  
           the patient's age,family status, etc. 
 
ATTENTION 
 
21.   Social Inattentiveness                                                                                             0  1  2  3  4  5 
        The patient appears uninvolved or unengaged. He may seem “spacy.” 
 
22.   Inattentiveness During Mental Status Training                                                 0  1  2  3  4  5 
        Tests of  “serial 7s” (at least five subtractions) and spelling “world” 
        backwards. Score: 2=1 error; 3=2 errors; 4=3 errors 
 
23.   Global Rating of Attention                                                                                    0  1  2  3  4  5 
         This rating should assess the patient’s overall concentration, clinically  
         and on tests. 
____________________________________________________________________________________________________________________________ 
*Modified 10-2-00 by the UCLA Center for Research on Treatment and Rehabilitation of Psychosis 
**Copyright Nancy C. Andreasen, M.D., Ph.D., 1984  
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APPENDIX E 
GLMM with Medication Adherence Ratings Preceding SANS Affective Flattening Ratings 
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Time Lag Estimate Standard Error of 
Estimate 
df (Numerator, 
Denominator) 
F Significance 
(p)  
12 months prior .201 .078 (1,159) 6.7 .011 
11 months prior .050 .068 (1,266) 0.6 .459 
10 months prior .092 .061 (1,353) 2.3 .131 
9 months prior -.029 .052 (1,429) 0.3 .583 
8 months prior .022 .045 (1,509) 0.2 .624 
7 months prior -.000 .040 (1,593) 0.0 .996 
6 months prior .006 .037 (1,682) 0.0 .868 
5 months prior .048 .035 (1,780) 1.9 .172 
4 months prior .074 .034 (1,878) 4.7 .031 
3 months prior .036 .033 (1,973) 1.2 .271 
2 months prior .060 .033 (1,1073) 3.4 .068 
1 month prior .076 .032 (1,1168) 5.6 .018 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
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APPENDIX F 
GLMM with Medication Adherence Ratings Preceding SANS Alogia Ratings 
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Time Lag Estimate Standard Error of 
Estimate 
df (Numerator, 
Denominator) 
F Significance 
(p)  
12 months prior .176 .066 (1,141) 7.3 .008 
11 months prior .136 .060 (1,253) 5.1 .024 
10 months prior .072 .057 (1,346) 1.6 .211 
9 months prior .005 .048 (1,420) 0.0 .923 
8 months prior .036 .042 (1,512) 0.7 .399 
7 months prior .017 .040 (1,605) 0.2 .678 
6 months prior .056 .036 (1,695) 2.4 .124 
5 months prior .043 .035 (1,792) 1.5 .216 
4 months prior .089 .034 (1,893) 6.9 .009 
3 months prior .075 .033 (1,985) 5.3 .022 
2 months prior .110 .032 (1,1086) 12.0 .001 
1 month prior .103 .031 (1,1183) 11.0 .001 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
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APPENDIX G 
GLMM with Medication Adherence Ratings Preceding SANS Avolition-Apathy Ratings 
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Time Lag Estimate Standard Error of 
Estimate 
df (Numerator, 
Denominator) 
F Significance 
(p)  
12 months prior .342 .100 (1,157) 11.8 .001 
11 months prior .078 .085 (1,257) 0.8 .359 
10 months prior .192 .074 (1,341) 6.7 .010 
9 months prior .173 .066 (1,427) 6.8 .010 
8 months prior .017 .059 (1,509) 0.1 .767 
7 months prior -.033 .054 (1,596) 0.4 .545 
6 months prior .014 .049 (1,685) 0.1 .777 
5 months prior -.020 .046 (1,782) 0.2 .670 
4 months prior -.038 .044 (1,883) 0.7 .397 
3 months prior .003 .043 (1,980) 0.0 .947 
2 months prior .059 .042 (1,1083) 2.0 .157 
1 month prior .096 .040 (1,1178) 5.9 .015 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  101 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX H 
GLMM with Medication Adherence Ratings Preceding SANS Anhedonia-Asociality Ratings 
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Time Lag Estimate Standard Error of 
Estimate 
df (Numerator, 
Denominator) 
F Significance 
(p)  
12 months prior .284 .094 (1,180) 9.1 .003 
11 months prior .037 .077 (1,267) 0.2 .633 
10 months prior .119 .068 (1,350) 3.1 .080 
9 months prior -.036 .058 (1,425) 0.4 .532 
8 months prior .000 .050 (1,507) 0.0 .999 
7 months prior .063 .045 (1,594) 2.0 .159 
6 months prior .042 .041 (1,680) 1.1 .300 
5 months prior .032 .040 (1,783) 0.7 .419 
4 months prior .043 .037 (1,877) 1.3 .252 
3 months prior .063 .035 (1,970) 3.2 074 
2 months prior .067 .034 (1,1067) 3.9 .047 
1 month prior .080 .032 (1,1162) 6.2 .013 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
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APPENDIX I 
GLMM with Medication Adherence Ratings Preceding SANS Attention Ratings 
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Time Lag Estimate Standard Error of 
Estimate 
df (Numerator, 
Denominator) 
F Significance 
(p)  
12 months prior .091 .100 (1,195) 0.8 .365 
11 months prior .126 .082 (1,282) 2.4 .127 
10 months prior .050 .075 (1,367) 0.4 .506 
9 months prior .012 .068 (1,455) 0.0 .862 
8 months prior -.013 .060 (1,541) 0.1 .825 
7 months prior .019 .053 (1,624) 0.1 .721 
6 months prior .021 .047 (1,707) 0.2 .194 
5 months prior .031 .044 (1,806) 0.5 .485 
4 months prior -.002 .042 (1,900) 0.0 .972 
3 months prior .081 .039 (1,990) 4.2 .041 
2 months prior .107 .038 (1,1088) 8.2 .004 
1 month prior .080 .036 (1,1181) 5.0 .026 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
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APPENDIX J 
GLMM with Medication Adherence Ratings Preceding BPRS Negative Symptom Factor Ratings 
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Time Lag Estimate Standard Error of 
Estimate 
df (Numerator, 
Denominator) 
F Significance 
(p)  
12 months prior .187 .054 (1,164) 12.1 .001 
11 months prior .011 .052 (1,280) 0.0 .840 
10 months prior .052 .045 (1,360) 1.3 .253 
9 months prior -.043 .038 (1,437) 1.3 .259 
8 months prior -.008 .034 (1,525) 0.1 .823 
7 months prior .032 .031 (1,616) 1.1 .299 
6 months prior .009 .028 (1,704) 0.1 .750 
5 months prior -.006 .026 (1,800) 0.0 .834 
4 months prior .011 .025 (1,894) 0.2 .649 
3 months prior .023 .024 (1,988) 0.9 .341 
2 months prior .031 .024 (1,1086) 1.7 .197 
1 month prior .049 .023 (1,1182) 4.5 .033 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
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APPENDIX K 
GLMM with Medication Adherence Ratings Preceding BPRS Self-Neglect Ratings 
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Time Lag Estimate Standard Error of 
Estimate 
df (Numerator, 
Denominator) 
F Significance 
(p)  
12 months prior .129 .050 (1,201) 6.7 .011 
11 months prior -.015 .038 (1,285) 0.2 .690 
10 months prior .068 .037 (1,364) 3.5 .062 
9 months prior .073 .032 (1,450) 5.1 .025 
8 months prior .035 .030 (1,538) 1.3 .247 
7 months prior .056 .029 (1,631) 3.6 .057 
6 months prior .009 .027 (1,719) 0.1 .733 
5 months prior -.010 .025 (1,814) 0.2 .702 
4 months prior .021 .025 (1,908) 0.7 .409 
3 months prior .076 .024 (1,998) 10.4 .001 
2 months prior .076 .022 (1,1097) 11.7 .001 
1 month prior .042 .021 (1,1190) 3.8 .052 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
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APPENDIX L 
GLMM with Medication Adherence Ratings Preceding BPRS Blunted Affect Ratings 
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Time Lag Estimate Standard Error of 
Estimate 
df (Numerator, 
Denominator) 
F Significance 
(p)  
12 months prior .171 .072 (1,152) 5.7 .018 
11 months prior .003 .069 (1,268) 0.0 .964 
10 months prior .132 .062 (1,356) 4.6 .033 
9 months prior -.078 .052 (1,432) 2.2 .137 
8 months prior .010 .046 (1,520) 0.0 .838 
7 months prior .028 .043 (1,608) 0.4 .509 
6 months prior -.012 .038 (1,690) 0.2 .675 
5 months prior .002 .035 (1,786) 0.0 .949 
4 months prior .023 .034 (1,885) 0.5 .495 
3 months prior -.004 .033 (1,978) 0.0 .905 
2 months prior .018 .032 (1,1077) 0.3 .576 
1 month prior .066 .032 (1,1172) 4.4 .037 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
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APPENDIX M 
GLMM with Medication Adherence Ratings Preceding BPRS Emotional Withdrawal Ratings 
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Time Lag Estimate Standard Error of 
Estimate 
df (Numerator, 
Denominator) 
F Significance 
(p)  
12 months prior .165 .071 (1,199) 5.4 .021 
11 months prior .044 .064 (1,284) 0.5 .491 
10 months prior .002 .057 (1,373) 0.0 .979 
9 months prior .011 .049 (1,457) 0.1 .817 
8 months prior .018 .043 (1,547) 0.2 .677 
7 months prior .097 .039 (1,635) 6.1 .014 
6 months prior .057 .036 (1,723) 2.5 .113 
5 months prior .024 .035 (1,814) 0.5 .482 
4 months prior .038 .033 (1,905) 1.4 .242 
3 months prior .050 .032 (1,998) 2.5 .112 
2 months prior .072 .030 (1,1097) 5.7 .017 
1 month prior .073 .029 (1,1191) 6.3 .013 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
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APPENDIX N 
GLMM with Medication Adherence Ratings Preceding BPRS Motor Retardation Ratings 
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Time Lag Estimate Standard Error of 
Estimate 
df (Numerator, 
Denominator) 
F Significance 
(p)  
12 months prior .195 .065 (1,182) 8.9 .003 
11 months prior .002 .057 (1,88) 0.0 .977 
10 months prior .058 .052 (1,374) 1.3 .259 
9 months prior -.035 .046 (1,459) 0.6 .447 
8 months prior -.027 .040 (1,546) 0.5 .494 
7 months prior -.018 .037 (1,637) 0.2 .624 
6 months prior -.007 .034 (1,724) 0.0 .838 
5 months prior -.035 .031 (1,816) 1.3 .263 
4 months prior -.020 .029 (1,908) 0.5 .497 
3 months prior .028 .028 (1,999) 1.0 .318 
2 months prior .007 .028 (1,1097) 1.1 .800 
1 month prior .013 .028 (1,1192) 0.2 .646 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
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APPENDIX O 
GLMM of SANS Affective Flattening Ratings with Subsequent Medication Adherence Ratings 
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Time Lag Estimate Standard Error of 
Estimate 
df (Numerator, 
Denominator) 
F Significance 
(p)  
12 months later .078 .134 (1,69) 0.3 .561 
11 months later -.118 .084 (1,149) 2.0 .158 
10 months later .040 .069 (1,231) 0.3 .566 
9 months later -.095 .058 (1,315) 2.7 .100 
8 months later -.088 .052 (1,404) 2.8 .095 
7 months later -.042 .052 (1,492) 0.7 .419 
6 months later -.060 .050 (1,582) 1.4 .232 
5 months later -.108 .044 (1,681) 6.0 .015 
4 months later -.093 .039 (1,779) 5.9 .015 
3 months later -.039 .035 (1,877) 1.2 .268 
2 months later -.009 .034 (1,984) 0.1 .778 
1 month later .031 .032 (1,1099) 0.9 .340 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
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APPENDIX P 
GLMM of SANS Attention Ratings with Subsequent Medication Adherence Ratings 
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Time Lag Estimate Standard Error of 
Estimate 
df (Numerator, 
Denominator) 
F Significance 
(p)  
12 months later -.022 .125 (1,69) 0.0 .862 
11 months later -.041 .079 (1,150) 0.3 .605 
10 months later -.034 .068 (1,234) 0.3 .568 
9 months later -.045 .064 (1,313) 0.5 .485 
8 months later .050 .060 (1,391) 0.7 .402 
7 months later -.033 .055 (1,478) 0.4 .548 
6 months later -.007 .053 (1,565) 0.0 .892 
5 months later -.025 .048 (1,658) 0.3 .611 
4 months later -.036 .042 (1,749) 0.7 .400 
3 months later -.030 .0393 (1,847) 0.6 .454 
2 months later .037 .038 (1,972) 1.0 .326 
1 month later .077 .036 (1,1092) 4.5 .034 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
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APPENDIX Q 
GLMM of SANS Alogia Ratings with Subsequent Medication Adherence Ratings 
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Time Lag Estimate Standard Error of 
Estimate 
df (Numerator, 
Denominator) 
F Significance 
(p)  
12 months later -.055 .122 (1,69) 0.2 .662 
11 months later -.069 .084 (1,149) 0.7 .416 
10 months later .067 .070 (1,235) 0.9 .342 
9 months later -.060 .059 (1,319) 1.0 .311 
8 months later -.143 .052 (1,404) 7.6 .006 
7 months later -.048 .049 (1,490) 1.0 .328 
6 months later -.033 .048 (1,572) 0.5 .489 
5 months later -.044 .043 (1,669) 1.1 .306 
4 months later -.026 .037 (1,765) 0.5 .478 
3 months later -.027 .034 (1,860) 0.6 .430 
2 months later -.011 .032 (1,981) 0.1 .735 
1 month later .058 .031 (1,1094) 3.4 .067 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
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APPENDIX R 
GLMM of SANS Avolition-Apathy Ratings with Subsequent Medication Adherence Ratings 
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Time Lag Estimate Standard Error of 
Estimate 
df (Numerator, 
Denominator) 
F Significance 
(p)  
12 months later .174 .134 (1,69) 1.7 .199 
11 months later .095 .092 (1,151) 1.1 .308 
10 months later .134 .080 (1,235) 2.8 .095 
9 months later .111 .071 (1,318) 2.4 .121 
8 months later .040 .065 (1,400) 0.4 .539 
7 months later -.045 .060 (1,488) 0.6 .455 
6 months later -.083 .057 (1,577) 2.2 .144 
5 months later -.052 .050 (1,678) 1.1 .301 
4 months later -.018 .045 (1,773) 0.2 .687 
3 months later -.027 .042 (1,871) 0.4 .512 
2 months later -.076 .041 (1,984) 3.5 .061 
1 month later -.034 .040 (1,1099) 0.7 .392 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
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APPENDIX S 
GLMM of SANS Anhedonia-Asociality Ratings with Subsequent Medication Adherence Ratings 
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Time Lag Estimate Standard Error of 
Estimate 
df (Numerator, 
Denominator) 
F Significance 
(p)  
12 months later -.105 .141 (1,69) 0.6 .461 
11 months later .119 .088 (1,149) 1.8 .178 
10 months later -.019 .075 (1,235) 0.1 .801 
9 months later .104 .065 (1,319) 2.6 .107 
8 months later .004 .057 (1,405) 0.0 .945 
7 months later -.045 .053 (1,492) 0.6 .427 
6 months later -.092 .050 (1,584) 3.4 .066 
5 months later -.002 .044 (1,682) 0.0 .966 
4 months later .064 .039 (1,779) 2.8 .097 
3 months later -.004 .035 (1,878) 0.0 .908 
2 months later -.025 .033 (1,983) 0.6 .453 
1 month later -.001 .032 (1,1099) 0.0 .981 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
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APPENDIX T 
GLMM of BPRS Negative Symptom Factor Ratings with Subsequent Medication Adherence 
Ratings 
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Time Lag Estimate Standard Error of 
Estimate 
df (Numerator, 
Denominator) 
F Significance 
(p)  
12 months later -.001 .096 (1,69) 0.0 .991 
11 months later -.045 .061 (1,151) 0.6 .462 
10 months later -.002 .051 (1,236) 0.0 .974 
9 months later -.030 .043 (1,320) 0.5 .485 
8 months later -.071 .038 (1,406) 3.5 .063 
7 months later -.047 .037 (1,493) 1.6 .212 
6 months later -.011 .036 (1,580) 0.1 .772 
5 months later -.049 .032 (1,679) 2.3 .127 
4 months later -.054 .028 (1,776) 3.8 .052 
3 months later -.026 .025 (1,871) 1.0 .306 
2 months later -.009 .024 (1,987) 0.2 .702 
1 month later .023 .023 (1,1102) 1.0 .329 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
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APPENDIX U 
GLMM of BPRS Self-Neglect Ratings with Subsequent Medication Adherence Ratings 
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Time Lag Estimate Standard Error of 
Estimate 
df (Numerator, 
Denominator) 
F Significance 
(p)  
12 months later -.012 .063 (1,69) 0.0 .847 
11 months later .003 .042 (1,151) 0.0 .936 
10 months later .015 .035 (1,236) 0.2 .661 
9 months later .014 .036 (1,303) 0.2 .699 
8 months later -.058 .034 (1,380) 2.8 .093 
7 months later -.093 .033 (1,476) 8.0 .005 
6 months later -.016 .032 (1,561) 0.3 .605 
5 months later .022 .028 (1,664) 0.6 .438 
4 months later .090 .024 (1,770) 13.8 .000 
3 months later .029 .023 (1,854) 1.6 .205 
2 months later .007 .021 (1,973) 0.1 .744 
1 month later .035 .021 (1,1084) 2.9 .090 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
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APPENDIX V 
GLMM of BPRS Blunted Affect Ratings with Subsequent Medication Adherence Ratings 
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Time Lag Estimate Standard Error of 
Estimate 
df (Numerator, 
Denominator) 
F Significance 
(p)  
12 months later .022 .131 (1,69) 0.0 .866 
11 months later -.031 .081 (1,150) 0.2 .701 
10 months later -.056 .068 (1,233) 0.7 .408 
9 months later -.053 .057 (1,317) 0.9 .352 
8 months later -.101 .052 (1,405) 3.7 .055 
7 months later -.065 .052 (1,494) 1.6 .206 
6 months later -.052 .049 (1,585) 1.2 .284 
5 months later -.105 .043 (1,684) 5.9 .016 
4 months later -.133 .038 (1,781) 9.0 .003 
3 months later -.067 .035 (1,880) 3.7 .054 
2 months later -.023 .033 (1,987) 0.5 .486 
1 month later .003 .032 (1,1102) 0.0 .931 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
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APPENDIX W 
GLMM of BPRS Emotional Withdrawal Ratings with Subsequent Medication Adherence 
Ratings 
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Time Lag Estimate Standard Error of 
Estimate 
df (Numerator, 
Denominator) 
F Significance 
(p)  
12 months later -.011 .100 (1,69) 0.0 .916 
11 months later -.018 .072 (1,138) 0.1 .807 
10 months later .044 .060 (1,216) 0.5 .467 
9 months later -.033 .054 (1,301) 0.4 .541 
8 months later -.065 .049 (1,381) 1.8 .179 
7 months later .013 .046 (1,468) 0.1 .774 
6 months later .093 .046 (1,528) 4.1 .042 
5 months later .067 .041 (1,635) 2.7 .099 
4 months later .029 .035 (1,736) 0.7 .408 
3 months later .015 .032 (1,834) 0.2 .649 
2 months later .023 .030 (1,964) 0.6 .441 
1 month later .088 .029 (1,1073) 9.2 .003 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
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APPENDIX X 
GLMM of BPRS Motor Retardation Ratings with Subsequent Medication Adherence Ratings 
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Time Lag Estimate Standard Error of 
Estimate 
df (Numerator, 
Denominator) 
F Significance 
(p)  
12 months later -.015 .117 (1,69) 0.0 .899 
11 months later -.033 .077 (1,152) 0.2 .669 
10 months later .014 .066 (1,235) 0.1 .829 
9 months later .014 .056 (1,317) 0.1 .807 
8 months later -.026 .049 (1,401) 0.3 .595 
7 months later -.077 .045 (1,489) 2.9 .088 
6 months later -.064 .042 (1,579) 2.3 .130 
5 months later -.100 .037 (1,675) 7.1 .008 
4 months later -.065 .033 (1,769) 3.9 .050 
3 months later -.018 .030 (1,862) 0.3 .561 
2 months later -.021 .029 (1,982) 0.5 .470 
1 month later -.020 .028 (1,1096) 0.5 .481 
Note. Light gray shading = p < 0.05, Dark gray shading = p < 0.01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  
